MeSH term
Frequency | Condition_Probility | Acute Disease | 48 | 2.0 |
Adult | 439 | 0.0 |
Comparative Study | 190 | 0.0 |
Humans | 1984 | 0.0 |
Leukemia/*therapy | 3 | 2.0 |
Research Support, Non-U.S. Gov't | 1178 | 0.0 |
Substrate Specificity | 5 | 0.0 |
Amino Acid Sequence | 114 | 0.0 |
Antigens, CD/analysis/*physiology | 5 | 17.0 |
B-Lymphocytes/*physiology | 6 | 4.0 |
Carrier Proteins/chemistry/*metabolism | 2 | 2.0 |
Cell Line | 167 | 0.0 |
Immunoglobulin Variable Region/genetics | 2 | 1.0 |
*Immunologic Memory | 14 | 10.0 |
*Intracellular Signaling Peptides and Proteins | 5 | 0.0 |
Lymphocyte Activation | 228 | 7.0 |
*Membrane Glycoproteins | 11 | 1.0 |
Molecular Sequence Data | 174 | 0.0 |
Phosphorylation | 83 | 1.0 |
Tyrosine/metabolism | 21 | 1.0 |
Up-Regulation | 17 | 0.0 |
Calcium/*metabolism | 16 | 2.0 |
Cell Division/drug effects/immunology | 3 | 4.0 |
Leukemia | 5 | 7.0 |
Signal Transduction/drug effects/*immunology | 2 | 5.0 |
T-Lymphocytes/drug effects/*immunology/*metabolism | 4 | 40.0 |
Tumor Cells, Cultured | 119 | 0.0 |
Up-Regulation/drug effects/immunology | 3 | 7.0 |
Antigens, CD/*immunology | 46 | 10.0 |
English Abstract | 100 | 0.0 |
Apoptosis/immunology | 4 | 4.0 |
Cell Communication/immunology | 4 | 5.0 |
Cell Cycle/immunology | 4 | 12.0 |
Cell Division | 72 | 1.0 |
Coculture Techniques | 14 | 2.0 |
Lymphocyte Activation/*immunology | 52 | 12.0 |
Male | 530 | 0.0 |
T-Lymphocytes/*immunology | 290 | 13.0 |
Autoimmunity | 3 | 2.0 |
Enzyme-Linked Immunosorbent Assay | 29 | 0.0 |
Female | 494 | 0.0 |
Follow-Up Studies | 18 | 0.0 |
Middle Aged | 346 | 0.0 |
Sex Factors | 3 | 0.0 |
T-Lymphocyte Subsets/immunology | 19 | 5.0 |
Animals | 397 | 0.0 |
Dendritic Cells/physiology | 2 | 6.0 |
RNA, Messenger/analysis | 25 | 0.0 |
T-Lymphocytes/*metabolism | 30 | 7.0 |
Antibodies, Monoclonal/immunology | 143 | 8.0 |
Antigens, Differentiation/*metabolism | 2 | 1.0 |
Cell Differentiation | 63 | 2.0 |
Cells, Cultured | 285 | 1.0 |
Dendritic Cells/*immunology | 6 | 2.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 3 | 0.0 |
Interleukin-4/pharmacology | 15 | 4.0 |
Interleukin-6/pharmacology | 6 | 2.0 |
Lipopolysaccharides/pharmacology | 4 | 0.0 |
Stem Cells/metabolism | 2 | 2.0 |
Tumor Necrosis Factor-alpha/pharmacology | 13 | 1.0 |
Antigens, CD2/biosynthesis | 8 | 80.0 |
Antigens, CD3/biosynthesis | 5 | 8.0 |
Antigens, CD45/biosynthesis | 4 | 7.0 |
Blotting, Western | 24 | 0.0 |
Cell Cycle | 10 | 0.0 |
Flow Cytometry | 261 | 4.0 |
Kinetics | 57 | 0.0 |
Mitosis | 5 | 1.0 |
Phenotype | 173 | 1.0 |
RNA/metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 461 | 0.0 |
T-Lymphocytes/*immunology/metabolism | 28 | 17.0 |
Time Factors | 73 | 0.0 |
Antigens, CD/*metabolism | 30 | 4.0 |
Antigens, CD2/metabolism | 22 | 78.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 27 | 23.0 |
Apoptosis/*immunology | 6 | 3.0 |
Cell Survival | 6 | 0.0 |
In Vitro | 156 | 2.0 |
Infant | 67 | 1.0 |
Mice | 195 | 0.0 |
Mice, Inbred BALB C | 35 | 1.0 |
Mice, Inbred C57BL | 15 | 0.0 |
Mice, Knockout | 7 | 0.0 |
Mice, Transgenic | 15 | 0.0 |
Signal Transduction | 91 | 1.0 |
Cyclophosphamide/administration & dosage | 7 | 3.0 |
DNA, Neoplasm/analysis | 12 | 1.0 |
Doxorubicin/administration & dosage | 5 | 2.0 |
Fatal Outcome | 27 | 4.0 |
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor/genetics | 4 | 33.0 |
Herpesvirus 4, Human/isolation & purification/physiology | 2 | 66.0 |
Killer Cells, Natural/*pathology | 13 | 44.0 |
Polymerase Chain Reaction | 28 | 0.0 |
Prednisone/administration & dosage | 6 | 7.0 |
RNA, Viral/analysis | 4 | 1.0 |
Tumor Markers, Biological/analysis | 6 | 0.0 |
Vincristine/administration & dosage | 7 | 4.0 |
Cell Lineage | 8 | 1.0 |
Diagnosis, Differential | 14 | 0.0 |
Mast Cells/pathology | 2 | 5.0 |
Prognosis | 35 | 0.0 |
Antigens, CD/immunology | 56 | 11.0 |
Antigens, CD2/*immunology | 34 | 94.0 |
Cytoplasm/immunology | 9 | 9.0 |
Aged | 218 | 0.0 |
Aged, 80 and over | 64 | 0.0 |
B-Lymphocytes/*pathology | 3 | 6.0 |
Biopsy | 30 | 1.0 |
Immunoenzyme Techniques | 48 | 1.0 |
In Situ Hybridization | 12 | 0.0 |
T-Lymphocytes/*pathology | 8 | 11.0 |
Tumor Markers, Biological/metabolism | 6 | 1.0 |
Antigens, CD56/*analysis | 7 | 22.0 |
Bone Marrow/pathology | 31 | 7.0 |
DNA Nucleotidylexotransferase/*analysis | 2 | 20.0 |
Immunophenotyping | 246 | 8.0 |
Lymph Nodes/pathology | 15 | 5.0 |
Skin/pathology | 9 | 3.0 |
*Cell Adhesion | 21 | 13.0 |
Immunohistochemistry | 75 | 0.0 |
Inflammation | 4 | 1.0 |
Myocardium/*pathology | 2 | 5.0 |
Antibodies, Monoclonal/*immunology | 58 | 7.0 |
Antibody Specificity | 17 | 1.0 |
Antigens, CD3/*immunology | 16 | 15.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 67 | 36.0 |
CD4-CD8 Ratio | 19 | 3.0 |
Cross Reactions | 8 | 0.0 |
Macaca mulatta/*immunology | 4 | 28.0 |
Adjuvants, Immunologic/pharmacology | 4 | 4.0 |
Antigens, CD19/analysis | 3 | 3.0 |
Antigens, CD20/*immunology | 2 | 16.0 |
B-Lymphocytes/*immunology | 27 | 3.0 |
Hemocyanin/immunology | 2 | 12.0 |
Immunoglobulins/biosynthesis | 6 | 5.0 |
Spleen/cytology/immunology | 3 | 4.0 |
*Apoptosis | 15 | 0.0 |
Intestinal Mucosa/*immunology | 12 | 13.0 |
*Lymphocyte Activation | 230 | 17.0 |
T-Lymphocytes/*immunology/physiology | 12 | 32.0 |
Severity of Illness Index | 7 | 0.0 |
Enzyme Inhibitors/pharmacology | 10 | 0.0 |
Sphingomyelin Phosphodiesterase/*metabolism | 2 | 11.0 |
Retrospective Studies | 14 | 0.0 |
Adolescent | 165 | 0.0 |
Antigens, CD2/*metabolism | 30 | 90.0 |
Cytotoxicity, Immunologic | 84 | 8.0 |
Down-Regulation | 20 | 1.0 |
Exercise/*physiology | 3 | 0.0 |
Exercise Test | 2 | 0.0 |
Leukocyte Count | 40 | 2.0 |
Membrane Glycoproteins/*genetics/metabolism | 2 | 2.0 |
RNA, Messenger/*metabolism | 6 | 0.0 |
Antineoplastic Agents/*administration & dosage | 3 | 5.0 |
Child, Preschool | 107 | 1.0 |
Combined Modality Therapy | 10 | 0.0 |
Fetal Blood | 3 | 2.0 |
Remission Induction | 20 | 3.0 |
Androstadienes/pharmacology | 5 | 1.0 |
Antigens, CD2/*physiology | 24 | 96.0 |
Antigens, CD28/*physiology | 9 | 9.0 |
Cell Division/physiology | 12 | 1.0 |
Enzyme Activation | 24 | 0.0 |
Enzyme Induction | 2 | 0.0 |
RNA, Messenger/biosynthesis | 7 | 0.0 |
Receptors, Antigen, T-Cell/immunology | 44 | 22.0 |
Signal Transduction/drug effects | 6 | 0.0 |
Thionucleotides/pharmacology | 2 | 3.0 |
Antigens, CD/*analysis | 89 | 11.0 |
Mast Cells/chemistry | 2 | 66.0 |
Antigens, CD2/chemistry/genetics/*immunology | 2 | 100.0 |
Conserved Sequence | 2 | 0.0 |
DNA, Complementary/genetics | 7 | 0.0 |
Erythrocytes/*immunology | 5 | 2.0 |
Monocytes/immunology | 22 | 5.0 |
Rosette Formation | 49 | 16.0 |
Species Specificity | 17 | 0.0 |
T-Lymphocytes/immunology | 76 | 5.0 |
Biological Markers/analysis | 12 | 1.0 |
Clone Cells | 49 | 4.0 |
Exocytosis/*immunology | 2 | 66.0 |
Jurkat Cells | 48 | 3.0 |
Membrane Proteins/*metabolism | 3 | 0.0 |
Microscopy, Immunoelectron | 3 | 0.0 |
Receptor-CD3 Complex, Antigen, T-Cell/*metabolism | 2 | 12.0 |
T-Lymphocytes/*immunology/metabolism/ultrastructure | 2 | 50.0 |
Antibodies, Monoclonal | 148 | 6.0 |
Antigens, CD | 13 | 9.0 |
Antigens, CD19 | 8 | 4.0 |
Antigens, CD2 | 416 | 89.0 |
Antigens, CD3 | 173 | 38.0 |
Antigens, Differentiation, B-Lymphocyte | 2 | 5.0 |
B-Lymphocytes/immunology | 28 | 3.0 |
*Cell Adhesion Molecules | 6 | 2.0 |
Erythrocytes | 2 | 4.0 |
Hematopoietic Stem Cell Transplantation/*adverse effects | 2 | 5.0 |
Histocompatibility Testing | 11 | 1.0 |
Lectins | 3 | 3.0 |
*Plant Lectins | 3 | 2.0 |
Sheep | 29 | 4.0 |
*Soybean Proteins | 2 | 12.0 |
*T-Lymphocytes/immunology | 3 | 42.0 |
Transplantation, Homologous | 15 | 2.0 |
Antigens, CD/analysis | 134 | 8.0 |
Bone Marrow Cells/immunology | 3 | 7.0 |
*Immunophenotyping | 27 | 15.0 |
Leukemia, B-Cell, Acute/immunology | 2 | 28.0 |
Antigens, CD/metabolism | 36 | 4.0 |
HLA-DR Antigens/metabolism | 7 | 4.0 |
3T3 Cells | 5 | 0.0 |
Base Sequence | 110 | 0.0 |
*Gene Expression Regulation | 11 | 0.0 |
Genetic Vectors/genetics | 2 | 0.0 |
Green Fluorescent Proteins | 4 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Retroviridae/genetics | 4 | 1.0 |
Sequence Deletion | 4 | 0.0 |
Transfection | 67 | 0.0 |
Antigens, CD2/*chemistry/genetics | 3 | 100.0 |
Chromosome Mapping | 18 | 0.0 |
Cloning, Molecular | 26 | 0.0 |
Expressed Sequence Tags | 2 | 0.0 |
Immunoglobulins/*chemistry/genetics | 2 | 100.0 |
Lymphocytes/metabolism | 3 | 1.0 |
Phosphotyrosine/metabolism | 7 | 1.0 |
Phylogeny | 3 | 0.0 |
Protein Binding | 22 | 0.0 |
Proto-Oncogene Proteins/metabolism | 3 | 0.0 |
RNA, Messenger/metabolism | 12 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 14 | 0.0 |
Sequence Homology, Amino Acid | 23 | 0.0 |
Two-Hybrid System Techniques | 3 | 0.0 |
*Leukemic Infiltration | 3 | 27.0 |
Apoptosis/drug effects/*immunology | 6 | 15.0 |
Receptors, Antigen, T-Cell, gamma-delta/immunology | 3 | 13.0 |
Receptors, Interleukin-2/*immunology | 2 | 4.0 |
T-Lymphocytes/*immunology/pathology | 7 | 12.0 |
Antigens, CD14/analysis | 2 | 1.0 |
B-Lymphocytes/pathology | 5 | 5.0 |
*Cell Communication | 5 | 6.0 |
Leukocytes, Mononuclear/immunology/*pathology | 2 | 33.0 |
Spleen/cytology | 3 | 1.0 |
Antigens, CD2/*chemistry | 4 | 100.0 |
Blotting, Northern | 29 | 0.0 |
Cell Adhesion | 72 | 5.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Immunoglobulins/*chemistry | 2 | 13.0 |
Models, Molecular | 29 | 1.0 |
Protein Structure, Tertiary | 14 | 0.0 |
Tissue Distribution | 10 | 0.0 |
Antigens, CD2/genetics/*physiology | 2 | 66.0 |
Cell Differentiation/genetics/immunology | 3 | 3.0 |
Cytokines/*biosynthesis | 17 | 4.0 |
Lymph Nodes/cytology/immunology | 3 | 12.0 |
Lymphocyte Activation/genetics | 5 | 5.0 |
Thymus Gland/cytology/immunology | 4 | 9.0 |
Antigens, Surface/immunology | 28 | 14.0 |
Cattle | 7 | 0.0 |
Dogs | 2 | 0.0 |
Fluorescent Antibody Technique, Indirect | 4 | 0.0 |
Cell Nucleus/pathology | 4 | 5.0 |
Cytoplasm/pathology | 2 | 7.0 |
*Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 3 | 25.0 |
HLA-DR Antigens/analysis | 26 | 4.0 |
Receptors, Interleukin-2/analysis | 24 | 9.0 |
*Adaptor Proteins, Signal Transducing | 13 | 0.0 |
*Adaptor Proteins, Vesicular Transport | 2 | 0.0 |
Cytotoxicity Tests, Immunologic | 31 | 7.0 |
*Cytotoxicity, Immunologic | 46 | 9.0 |
Interleukin-2/*pharmacology | 22 | 8.0 |
K562 Cells | 4 | 0.0 |
Killer Cells, Natural/drug effects/*immunology | 4 | 11.0 |
*Membrane Proteins | 9 | 0.0 |
Phosphoproteins/physiology | 2 | 3.0 |
Proto-Oncogene Proteins/physiology | 2 | 1.0 |
*Signal Transduction | 25 | 1.0 |
*Ubiquitin-Protein Ligases | 2 | 0.0 |
Antigens, CD3/analysis | 19 | 7.0 |
Biological Markers | 21 | 1.0 |
Karyotyping | 59 | 3.0 |
Killer Cells, Natural/*immunology | 68 | 13.0 |
Receptors, Immunologic/*analysis | 22 | 41.0 |
Cell Division/drug effects | 27 | 0.0 |
Immunosuppressive Agents/*pharmacology | 10 | 4.0 |
Lymphocyte Activation/*drug effects | 29 | 8.0 |
T-Lymphocytes/*drug effects/immunology | 14 | 15.0 |
DNA/metabolism | 5 | 0.0 |
Glycosylation | 23 | 2.0 |
Interleukin-2/pharmacology | 82 | 14.0 |
Phosphoprotein Phosphatase/*physiology | 2 | 15.0 |
Antigens, CD45/analysis | 17 | 6.0 |
Antigens, Differentiation/*analysis | 19 | 10.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 46 | 13.0 |
Cell Adhesion Molecules/analysis | 17 | 10.0 |
Receptors, Immunologic/analysis | 26 | 29.0 |
Receptors, Lymphocyte Homing/analysis | 5 | 15.0 |
Infusions, Intravenous | 7 | 1.0 |
Survival Rate | 13 | 0.0 |
Antigens, CD30 | 4 | 14.0 |
Antigens, CD56 | 23 | 32.0 |
Antigens, CD8 | 25 | 9.0 |
Killer Cells, Natural/immunology/*pathology | 4 | 30.0 |
Antibodies, Monoclonal/*analysis | 2 | 4.0 |
Analysis of Variance | 7 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Cross-Sectional Studies | 4 | 0.0 |
Risk Factors | 7 | 0.0 |
Microscopy, Electron | 26 | 1.0 |
Microscopy, Fluorescence | 9 | 0.0 |
Antibodies, Monoclonal/pharmacology | 50 | 6.0 |
Epitopes/*analysis | 3 | 1.0 |
Erythrocytes/immunology | 23 | 9.0 |
Fetal Blood/cytology | 8 | 4.0 |
*Gene Expression | 4 | 0.0 |
Histamine Release | 4 | 6.0 |
Leukemia, Mast-Cell/*immunology | 2 | 100.0 |
Lung/immunology | 2 | 6.0 |
Mast Cells/*immunology | 2 | 7.0 |
Skin/immunology | 4 | 4.0 |
Stem Cells | 3 | 2.0 |
Chromosome Aberrations | 24 | 4.0 |
Cytogenetic Analysis | 4 | 3.0 |
Gene Rearrangement, T-Lymphocyte | 27 | 26.0 |
In Situ Hybridization, Fluorescence | 18 | 0.0 |
Mice, SCID | 10 | 1.0 |
Translocation, Genetic | 10 | 1.0 |
*Tumor Cells, Cultured | 2 | 2.0 |
Glycoproteins/*analysis | 2 | 2.0 |
Lymphocytes/*immunology | 29 | 7.0 |
Antigens, CD7/*metabolism | 3 | 30.0 |
Chromosomes, Human, Pair 21 | 2 | 1.0 |
Chromosomes, Human, Pair 8 | 2 | 1.0 |
Gene Rearrangement | 19 | 4.0 |
Oncogene Proteins, Fusion/*genetics | 4 | 2.0 |
*Polyploidy | 2 | 7.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Translocation, Genetic/*genetics | 4 | 1.0 |
*Antigens, CD | 20 | 2.0 |
Carrier Proteins/metabolism | 5 | 0.0 |
Cytotoxicity, Immunologic/*immunology | 2 | 4.0 |
Interferon Type II/*secretion | 3 | 15.0 |
MAP Kinase Kinase 1 | 2 | 1.0 |
Phosphoproteins/metabolism | 11 | 1.0 |
*Receptors, Immunologic | 7 | 4.0 |
Signal Transduction/*immunology | 21 | 5.0 |
Transcription Factor AP-1/metabolism | 2 | 0.0 |
Transcription, Genetic/immunology | 3 | 3.0 |
p38 Mitogen-Activated Protein Kinases | 5 | 0.0 |
ras Proteins/physiology | 2 | 6.0 |
Antigens, CD2/*genetics | 8 | 100.0 |
Gene Duplication | 2 | 1.0 |
Lymphocyte Subsets/*immunology | 15 | 11.0 |
Child | 146 | 1.0 |
Interferon Type II/biosynthesis | 18 | 3.0 |
Interleukin-4/secretion | 3 | 7.0 |
Interleukin-5/secretion | 2 | 25.0 |
Phytohemagglutinins/*pharmacology | 4 | 11.0 |
Skin Tests | 5 | 2.0 |
Antigens, CD4/biosynthesis | 4 | 4.0 |
Antigens, CD8/biosynthesis | 4 | 11.0 |
Blotting, Southern | 33 | 1.0 |
*Chromosome Aberrations | 14 | 2.0 |
*Chromosome Deletion | 3 | 0.0 |
*Chromosomes, Human, Pair 6 | 2 | 0.0 |
Gene Deletion | 3 | 0.0 |
Herpesvirus 4, Human/genetics | 7 | 10.0 |
Killer Cells, Natural/*cytology | 6 | 26.0 |
Lymphoma/*genetics | 2 | 4.0 |
Binding, Competitive | 33 | 1.0 |
Calcium/antagonists & inhibitors/metabolism | 2 | 18.0 |
Cholera Toxin/pharmacology | 4 | 5.0 |
Electrophoresis, Polyacrylamide Gel | 19 | 0.0 |
Immunoblotting | 15 | 0.0 |
Lectins/*pharmacology | 2 | 5.0 |
Membrane Glycoproteins/analysis | 12 | 4.0 |
Plant Lectins | 3 | 6.0 |
Protein Kinase Inhibitors | 5 | 3.0 |
Cell Adhesion/drug effects | 6 | 1.0 |
Interferon Type II/pharmacology | 12 | 2.0 |
Phytohemagglutinins/pharmacology | 49 | 9.0 |
Protein Binding/drug effects | 4 | 1.0 |
Sensitivity and Specificity | 11 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 70 | 4.0 |
Antigens, CD2/analysis | 27 | 67.0 |
Antigens, CD4/analysis | 24 | 5.0 |
Antigens, CD5/analysis | 5 | 11.0 |
Antigens, CD7/analysis | 4 | 21.0 |
Antigens, CD8/analysis | 22 | 9.0 |
*Flow Cytometry | 12 | 7.0 |
Receptors, Antigen, T-Cell/analysis | 19 | 18.0 |
Antigens, Neoplasm/*analysis | 19 | 4.0 |
Lymphatic Metastasis | 2 | 0.0 |
Skin Neoplasms/immunology/*pathology | 2 | 7.0 |
Antigens, CD56/analysis | 10 | 15.0 |
Drug Synergism | 9 | 0.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor/genetics | 2 | 28.0 |
Genotype | 17 | 0.0 |
Leukemia, Lymphocytic, Acute/*immunology | 3 | 11.0 |
Lymphoma/immunology/*pathology | 2 | 40.0 |
Amino Acid Substitution | 2 | 0.0 |
Binding Sites | 38 | 0.0 |
Chromatography, Gel | 5 | 0.0 |
Electrostatics | 2 | 1.0 |
Magnetic Resonance Spectroscopy | 7 | 1.0 |
Mutation | 19 | 0.0 |
Structure-Activity Relationship | 15 | 0.0 |
Thermodynamics | 5 | 1.0 |
COS Cells | 6 | 0.0 |
Immunoglobulins/chemistry | 6 | 24.0 |
Interferon Type II/*biosynthesis | 6 | 3.0 |
Thymus Gland/immunology | 7 | 10.0 |
Models, Immunological | 4 | 1.0 |
*DNA-Binding Proteins | 5 | 0.0 |
Enzyme Precursors/metabolism | 2 | 1.0 |
Nuclear Proteins/*metabolism | 3 | 0.0 |
Phosphoproteins/*metabolism | 5 | 1.0 |
Protein-Tyrosine Kinase/metabolism | 14 | 1.0 |
*RNA-Binding Proteins | 4 | 1.0 |
Receptors, Antigen, T-Cell/metabolism | 13 | 7.0 |
Antigen Presentation | 3 | 0.0 |
Antigens, CD58/physiology | 4 | 57.0 |
Antigens, CD80/physiology | 4 | 12.0 |
Cell Differentiation/drug effects | 12 | 1.0 |
Cell Line, Transformed | 19 | 1.0 |
Interleukin-1/pharmacology | 20 | 3.0 |
L Cells (Cell Line) | 8 | 3.0 |
Lymphokines/secretion | 2 | 5.0 |
Receptors, IgG/physiology | 4 | 10.0 |
Recombinant Proteins/pharmacology | 26 | 1.0 |
Antigens, CD28/immunology/*metabolism | 2 | 14.0 |
Antigens, Differentiation/metabolism | 2 | 1.0 |
Antigens, Differentiation, B-Lymphocyte/metabolism | 2 | 3.0 |
Cytokines/biosynthesis | 19 | 3.0 |
*Hydrogen-Ion Concentration | 2 | 7.0 |
*Immunoconjugates | 8 | 2.0 |
Receptors, Interleukin-2/metabolism | 24 | 13.0 |
T-Lymphocytes, Cytotoxic/immunology | 18 | 4.0 |
Cell Adhesion Molecules/*metabolism | 17 | 6.0 |
Chromosomes, Human, Pair 1/genetics | 2 | 1.0 |
Gene Expression | 37 | 0.0 |
Leukocytes/immunology | 4 | 3.0 |
Molecular Structure | 3 | 0.0 |
Multigene Family | 4 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Receptors, Immunologic/chemistry/genetics/*metabolism | 2 | 25.0 |
CD4-Positive T-Lymphocytes/*metabolism | 6 | 6.0 |
CD8-Positive T-Lymphocytes/*metabolism | 2 | 5.0 |
Leukemia, T-Cell/immunology | 3 | 42.0 |
*T-Lymphocyte Subsets | 6 | 8.0 |
Epitopes/chemistry | 2 | 2.0 |
Models, Chemical | 2 | 0.0 |
CD4 Lymphocyte Count | 4 | 0.0 |
Clinical Trials | 2 | 0.0 |
Psoriasis/*drug therapy/immunology | 2 | 50.0 |
Treatment Outcome | 20 | 0.0 |
Antigens, CD2/blood | 4 | 80.0 |
Antigens, CD4/blood | 3 | 5.0 |
Antigens, CD8/blood | 2 | 5.0 |
Biological Markers/blood | 6 | 0.0 |
Interleukin-2/blood | 2 | 2.0 |
Tumor Necrosis Factor-alpha/*analysis | 2 | 0.0 |
Antigens, CD2/physiology | 16 | 66.0 |
Antigens, CD3/physiology | 17 | 22.0 |
Herpesvirus 2, Saimiriine/*physiology | 3 | 33.0 |
Lymphocyte Activation/*physiology | 13 | 15.0 |
Membrane Proteins/metabolism | 5 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Antigens, CD2/*biosynthesis | 8 | 100.0 |
Cell Aggregation/drug effects | 2 | 4.0 |
Cytokines/*pharmacology | 4 | 1.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Glucocorticoids/*pharmacology | 4 | 2.0 |
Interleukin-7/pharmacology | 7 | 16.0 |
Lymphocyte Activation/drug effects | 47 | 8.0 |
Lymphocyte Function-Associated Antigen-1/*biosynthesis | 2 | 40.0 |
Staurosporine/pharmacology | 2 | 1.0 |
src-Family Kinases/metabolism | 2 | 1.0 |
Cell Survival/drug effects | 7 | 0.0 |
DNA Primers | 9 | 0.0 |
Rats | 51 | 0.0 |
Antigens, CD2/*analysis | 5 | 83.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 9 | 2.0 |
*Immunohistochemistry | 3 | 3.0 |
Serine Endopeptidases/analysis | 6 | 17.0 |
Carrier Proteins/immunology | 3 | 7.0 |
Lymphocyte Activation/immunology | 38 | 7.0 |
Antigens, CD/physiology | 24 | 11.0 |
Antigens, Surface/biosynthesis | 6 | 10.0 |
Genetic Vectors | 8 | 0.0 |
Integrin alpha4 | 2 | 5.0 |
Integrin alpha4beta1 | 3 | 3.0 |
Integrins/*physiology | 5 | 5.0 |
Receptors, Lymphocyte Homing/*physiology | 2 | 6.0 |
Cell Membrane/immunology | 11 | 4.0 |
Receptors, Immunologic/*immunology/metabolism | 3 | 23.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 50 | 0.0 |
Cell Count | 8 | 0.0 |
Enzyme Precursors/analysis | 2 | 28.0 |
Immunophenotyping/*methods | 7 | 10.0 |
Antibodies, Monoclonal/metabolism | 5 | 1.0 |
Antigens, CD3/metabolism | 11 | 6.0 |
Antigens, CD58/metabolism | 3 | 18.0 |
Calcium/metabolism | 57 | 3.0 |
Cross-Linking Reagents/pharmacology | 4 | 2.0 |
Cytoplasm/metabolism | 10 | 1.0 |
Ligands | 48 | 1.0 |
Point Mutation | 6 | 0.0 |
Protein Conformation | 36 | 1.0 |
B-Lymphocytes/chemistry/immunology | 2 | 25.0 |
DNA, Complementary/chemistry/isolation & purification | 2 | 4.0 |
Immunosorbent Techniques | 7 | 2.0 |
Leukocytes/*chemistry | 3 | 11.0 |
Lymph Nodes/chemistry | 2 | 8.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Sequence Homology | 2 | 0.0 |
Spleen/chemistry | 2 | 8.0 |
T-Lymphocytes/chemistry | 4 | 13.0 |
Tumor Markers, Biological/*analysis | 20 | 2.0 |
Age Factors | 17 | 0.0 |
Antigens, Differentiation/*biosynthesis | 2 | 6.0 |
Immunophenotyping/methods/statistics & numerical data | 2 | 100.0 |
Receptors, Cell Surface/*biosynthesis | 3 | 5.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 18 | 3.0 |
Asparaginase/administration & dosage | 2 | 9.0 |
*Bone Marrow Transplantation | 16 | 4.0 |
Cytarabine/administration & dosage | 7 | 8.0 |
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 5 | 15.0 |
Prednisolone/administration & dosage | 2 | 2.0 |
Receptors, Antigen, T-Cell, gamma-delta/*genetics | 3 | 21.0 |
ADP-ribosyl Cyclase | 8 | 1.0 |
Antigens, CD/*blood | 3 | 1.0 |
Antigens, CD2/*blood | 3 | 100.0 |
Antigens, CD45/blood | 2 | 8.0 |
Blood Transfusion/*adverse effects | 2 | 3.0 |
CD4-Positive T-Lymphocytes/immunology | 24 | 2.0 |
HLA Antigens/genetics | 2 | 0.0 |
HLA-DR Antigens/blood | 3 | 5.0 |
Histocompatibility Antigens Class I/genetics | 2 | 2.0 |
Immunologic Memory | 12 | 4.0 |
Reference Values | 29 | 0.0 |
Regression Analysis | 4 | 0.0 |
T-Lymphocyte Subsets/*immunology | 43 | 7.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 9 | 4.0 |
Antigens, Differentiation, Myelomonocytic | 2 | 7.0 |
Killer Cells, Natural/*immunology/pathology | 4 | 33.0 |
Prednisone/therapeutic use | 3 | 2.0 |
Antibodies/*immunology | 3 | 2.0 |
Antigens, CD58/immunology | 4 | 57.0 |
Epitope Mapping | 2 | 0.0 |
Sequence Analysis, Protein | 2 | 1.0 |
T-Lymphocytes, Suppressor-Effector/*immunology | 8 | 8.0 |
Brain Neoplasms/metabolism | 2 | 8.0 |
Embryonic and Fetal Development | 3 | 0.0 |
Nerve Tissue Proteins/genetics/*metabolism | 2 | 1.0 |
Chromosome Banding | 9 | 1.0 |
*Mutation | 4 | 0.0 |
Protein Kinase C/*metabolism | 6 | 2.0 |
Signal Transduction/genetics | 2 | 0.0 |
T-Lymphocyte Subsets | 9 | 6.0 |
Antigens, CD/biosynthesis | 10 | 3.0 |
Antigens, Differentiation/biosynthesis | 2 | 3.0 |
Chronic Disease | 14 | 0.0 |
Inflammation Mediators/metabolism | 2 | 2.0 |
Organ Specificity | 6 | 0.0 |
Antigen-Presenting Cells/immunology | 34 | 12.0 |
Antigens, CD2/immunology | 25 | 80.0 |
Antigens, CD28/immunology | 9 | 6.0 |
Antigens, CD3/immunology | 21 | 7.0 |
Leukocytes, Mononuclear/immunology | 17 | 6.0 |
Lymph Nodes/cytology/*immunology | 2 | 28.0 |
Receptor-CD3 Complex, Antigen, T-Cell/immunology | 5 | 20.0 |
Receptors, Interleukin-2/immunology | 7 | 11.0 |
Acquired Immunodeficiency Syndrome/*immunology | 6 | 2.0 |
Interleukin-10/physiology | 2 | 8.0 |
Monocytes/*immunology/pathology | 2 | 18.0 |
Receptors, IgE/*blood | 2 | 28.0 |
Antigens, CD34/*analysis | 3 | 1.0 |
Cohort Studies | 5 | 0.0 |
Granulocytes/pathology | 2 | 6.0 |
*Protein-Tyrosine Kinase | 3 | 0.0 |
*Proto-Oncogene Proteins | 6 | 0.0 |
Antibodies, Monoclonal/analysis | 3 | 3.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
*Chromosome Mapping | 4 | 0.0 |
Gene Library | 3 | 0.0 |
*In Situ Hybridization, Fluorescence | 2 | 1.0 |
Metaphase | 2 | 1.0 |
Antibodies, Monoclonal/immunology/*pharmacology | 2 | 4.0 |
Heart Transplantation/immunology | 7 | 41.0 |
Immunity, Cellular | 31 | 4.0 |
Fluorescein-5-isothiocyanate | 4 | 2.0 |
Leukocyte Count/*methods | 2 | 25.0 |
CHO Cells | 24 | 1.0 |
Gene Expression Regulation/immunology | 5 | 3.0 |
Hamsters | 34 | 0.0 |
Interleukin-2/genetics | 5 | 5.0 |
*Nuclear Proteins | 10 | 0.0 |
Promoter Regions (Genetics)/*immunology | 2 | 4.0 |
Protein Binding/genetics/immunology | 6 | 7.0 |
Signal Transduction/*genetics/*immunology | 3 | 33.0 |
Trans-Activation (Genetics)/*immunology | 4 | 21.0 |
Cell Membrane/immunology/metabolism | 2 | 1.0 |
Down-Regulation/genetics/*immunology | 2 | 10.0 |
Signal Transduction/genetics/*immunology | 3 | 3.0 |
Lymphoma, B-Cell/*immunology | 2 | 5.0 |
Immunophenotyping/*standards | 3 | 25.0 |
Questionnaires | 4 | 0.0 |
Amino Acid Motifs | 3 | 0.0 |
Killer Cells, Natural/*metabolism | 6 | 10.0 |
Sequence Alignment | 12 | 0.0 |
Apoptosis/*drug effects/*immunology | 2 | 25.0 |
Gene Expression/drug effects | 8 | 1.0 |
RNA, Messenger/genetics/metabolism | 9 | 0.0 |
Receptors, Antigen, T-Cell/genetics/*metabolism | 2 | 11.0 |
Antigens, CD/analysis/genetics | 2 | 6.0 |
Antigens, CD2/analysis/genetics | 3 | 100.0 |
Antigens, CD7/analysis/genetics | 2 | 100.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/genetics | 3 | 60.0 |
Gene Expression Regulation | 18 | 0.0 |
Immunity, Cellular/immunology | 2 | 3.0 |
Immunoglobulin Isotypes/analysis | 3 | 20.0 |
Lymph Nodes/immunology | 2 | 2.0 |
Molecular Weight | 37 | 1.0 |
Cell Differentiation/immunology | 12 | 3.0 |
Dose-Response Relationship, Immunologic | 28 | 5.0 |
Binding Sites/genetics | 2 | 0.0 |
Cell Nucleus/metabolism | 6 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 2 | 1.0 |
DNA Footprinting | 2 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 2 | 0.0 |
Deoxyribonuclease I | 2 | 1.0 |
Nuclear Proteins/metabolism | 4 | 0.0 |
Transcription, Genetic | 28 | 0.0 |
Enzyme Induction/drug effects | 2 | 0.0 |
HLA-DR Antigens/biosynthesis | 2 | 2.0 |
Interferon-gamma, Recombinant/*pharmacology | 2 | 1.0 |
Interleukin-4/*pharmacology | 5 | 2.0 |
Antigens, Surface/metabolism | 10 | 8.0 |
Bone Marrow Cells | 23 | 5.0 |
Bone Marrow Purging/*methods | 4 | 11.0 |
Cytotoxicity, Immunologic/*drug effects | 6 | 8.0 |
Leukocytes, Mononuclear | 3 | 6.0 |
Tumor Cells, Cultured/drug effects | 3 | 0.0 |
Cell Communication/*physiology | 2 | 3.0 |
Extracellular Matrix/physiology | 2 | 2.0 |
Integrins/physiology | 4 | 5.0 |
Antibodies/pharmacology | 8 | 2.0 |
Antigens, CD2/immunology/*physiology | 6 | 100.0 |
Cytokines/pharmacology | 8 | 2.0 |
Killer Cells, Natural/*immunology/metabolism | 4 | 10.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/metabolism | 3 | 5.0 |
Promoter Regions (Genetics) | 10 | 0.0 |
Trans-Activators/*metabolism | 3 | 0.0 |
CD8-Positive T-Lymphocytes/immunology | 5 | 1.0 |
Interferon Type II/secretion | 8 | 7.0 |
Killer Cells, Natural/cytology/*immunology | 3 | 10.0 |
*Lectins, C-Type | 3 | 1.0 |
Membrane Glycoproteins/*immunology | 17 | 9.0 |
Receptors, Immunologic/immunology | 52 | 50.0 |
DNA-Binding Proteins/genetics | 4 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
Antigens, CD18/*metabolism | 3 | 15.0 |
Antigens, Differentiation, Myelomonocytic/*metabolism | 3 | 5.0 |
Apoptosis | 9 | 0.0 |
DNA Nucleotidylexotransferase/*metabolism | 2 | 33.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Protein-Tyrosine Kinase/*physiology | 6 | 4.0 |
Proto-Oncogene Proteins/*physiology | 4 | 1.0 |
Signal Transduction/immunology | 19 | 5.0 |
Apoptosis/drug effects | 4 | 0.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
Infant, Newborn | 35 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 7 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 3 | 0.0 |
Transcription Factors/*metabolism | 3 | 0.0 |
Interleukin-2/biosynthesis | 49 | 11.0 |
Transduction, Genetic | 2 | 0.0 |
Immunohistochemistry/methods | 4 | 0.0 |
Immunophenotyping/methods | 5 | 10.0 |
Polymerase Chain Reaction/methods | 7 | 0.0 |
Polymorphism, Single-Stranded Conformational | 4 | 0.0 |
Receptors, Antigen, T-Cell/genetics/immunology | 3 | 23.0 |
Drug Therapy, Combination | 7 | 0.0 |
Injections, Intramuscular | 3 | 1.0 |
Lupus Erythematosus, Systemic/blood/drug therapy/*immunology | 2 | 33.0 |
Lymphocyte Count | 26 | 3.0 |
Interferon Alfa-2b/*therapeutic use | 2 | 5.0 |
Chromosomes, Human, Pair 17/*genetics | 2 | 1.0 |
*Translocation, Genetic | 13 | 1.0 |
Swine | 12 | 0.0 |
Lymphocyte Subsets/*cytology | 2 | 8.0 |
Antigens, CD28/*immunology | 6 | 4.0 |
Interferons/*pharmacology | 2 | 2.0 |
Leukemia, Lymphocytic/*pathology | 3 | 15.0 |
Lymphoma/*pathology | 2 | 9.0 |
Skin Neoplasms/*pathology | 4 | 4.0 |
Antibodies, Monoclonal/*pharmacology | 17 | 8.0 |
Arthritis, Rheumatoid/*immunology | 4 | 1.0 |
Mitogens/pharmacology | 14 | 5.0 |
Mice, Inbred CBA | 5 | 1.0 |
Phospholipase C/physiology | 2 | 7.0 |
Protein Kinase C/physiology | 12 | 7.0 |
Cyclosporine/pharmacology | 16 | 7.0 |
Dexamethasone/pharmacology | 5 | 1.0 |
Tacrolimus/pharmacology | 4 | 8.0 |
Phosphoproteins/*immunology/metabolism | 2 | 50.0 |
Antigens, CD28/analysis | 2 | 5.0 |
*Blood Preservation | 2 | 3.0 |
*Cryopreservation | 2 | 3.0 |
Lymphocyte Culture Test, Mixed | 24 | 3.0 |
Protein Biosynthesis | 7 | 0.0 |
Antigens, CD58/pharmacology | 3 | 100.0 |
Antigens, CD80/pharmacology | 2 | 22.0 |
Antigens, Viral/immunology | 5 | 4.0 |
Epitopes, T-Lymphocyte/*immunology | 2 | 3.0 |
Human T-lymphotropic virus 1/*immunology | 3 | 15.0 |
Peptide Fragments/immunology | 2 | 0.0 |
Staining and Labeling | 16 | 2.0 |
Flow Cytometry/*methods | 13 | 5.0 |
Leukocytes/*cytology | 2 | 10.0 |
Lymphocytes | 2 | 1.0 |
Antigens, CD2/*chemistry/*physiology | 2 | 100.0 |
*Lymphocyte Activation/genetics | 4 | 14.0 |
Tumor Necrosis Factor-alpha/secretion | 6 | 5.0 |
Blood Platelets/immunology | 3 | 4.0 |
Chromosomes, Human, Pair 3 | 2 | 1.0 |
Peroxidase/analysis | 4 | 6.0 |
*Immunocompetence | 3 | 20.0 |
*Nutritional Status | 4 | 5.0 |
Dermatitis, Atopic/*immunology | 3 | 7.0 |
Interleukin-10/biosynthesis | 3 | 2.0 |
Interleukin-13/biosynthesis | 2 | 11.0 |
Interleukin-4/biosynthesis | 3 | 2.0 |
Interleukin-5/biosynthesis | 2 | 5.0 |
Interleukin-6/biosynthesis | 5 | 2.0 |
Mitogen-Activated Protein Kinases/immunology | 2 | 28.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Immunologic Deficiency Syndromes/genetics/immunology | 2 | 28.0 |
Leukocytes, Mononuclear/immunology/metabolism | 3 | 7.0 |
Linkage (Genetics) | 3 | 0.0 |
Lymphocyte Activation/genetics/*immunology | 2 | 11.0 |
Receptors, Immunologic/biosynthesis/*physiology | 2 | 33.0 |
Syndrome | 5 | 0.0 |
Monocytes/drug effects/*metabolism | 2 | 1.0 |
Antigens, CD/*genetics | 7 | 2.0 |
DNA, Complementary | 3 | 0.0 |
Leukocytes/*immunology | 11 | 8.0 |
Membrane Glycoproteins/*genetics | 3 | 0.0 |
Lymphocyte Function-Associated Antigen-1/*metabolism | 7 | 25.0 |
Receptors, Antigen, T-Cell, gamma-delta/*metabolism | 2 | 12.0 |
Aging/*immunology | 5 | 4.0 |
Killer Cells, Natural/immunology | 38 | 9.0 |
*Hip Prosthesis | 2 | 6.0 |
Killer Cells, Natural | 5 | 11.0 |
*Lymphocyte Count | 3 | 6.0 |
Lymphocyte Subsets | 8 | 4.0 |
*Chromosomes, Human, Pair 4 | 3 | 1.0 |
Leukemia, T-Cell, Acute/*genetics | 2 | 5.0 |
*Trisomy | 2 | 1.0 |
*Chromosomes, Human, Pair 14 | 6 | 3.0 |
Immunoglobulins, Heavy-Chain/*genetics | 2 | 1.0 |
Leukemia, Lymphocytic, Acute/*genetics | 2 | 2.0 |
Graft Rejection/immunology/*prevention & control | 3 | 15.0 |
Mice, Inbred NOD | 2 | 0.0 |
Skin/cytology/immunology | 3 | 16.0 |
Cell Separation | 43 | 4.0 |
Dendritic Cells/cytology/*immunology | 2 | 3.0 |
Histocompatibility Antigens Class II/*metabolism | 4 | 7.0 |
Isoantigens | 2 | 7.0 |
Swine, Miniature | 4 | 10.0 |
Antigens, CD4/*immunology | 3 | 0.0 |
Antigens, CD8/*immunology | 3 | 5.0 |
Interleukin-7/*immunology | 2 | 33.0 |
T-Lymphocyte Subsets/*immunology/pathology | 2 | 9.0 |
Kuwait/epidemiology | 2 | 25.0 |
*Lymphocyte Subsets | 11 | 12.0 |
Antigens, CD/genetics | 5 | 3.0 |
Consanguinity | 2 | 0.0 |
Immunologic Deficiency Syndromes/*genetics/immunology | 2 | 13.0 |
Liver/immunology/pathology | 3 | 17.0 |
Cell Adhesion/physiology | 6 | 2.0 |
Cross-Linking Reagents | 15 | 4.0 |
Protein-Tyrosine Kinase/*metabolism | 17 | 2.0 |
Cell Adhesion Molecules/*biosynthesis | 5 | 5.0 |
Lymphocyte Function-Associated Antigen-1/biosynthesis | 5 | 23.0 |
Antilymphocyte Serum/*therapeutic use | 3 | 10.0 |
Azathioprine/therapeutic use | 4 | 10.0 |
Cyclosporine/therapeutic use | 3 | 4.0 |
Graft Rejection/prevention & control | 5 | 12.0 |
Lymphocyte Subsets/*drug effects | 4 | 20.0 |
Rabbits | 12 | 0.0 |
Survival Analysis | 9 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Monocytes/*immunology | 11 | 2.0 |
Transcription, Genetic/drug effects | 2 | 0.0 |
Bone Marrow/drug effects | 2 | 2.0 |
Drug Administration Schedule | 4 | 0.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Double-Blind Method | 7 | 0.0 |
Dimerization | 6 | 0.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/*metabolism | 2 | 5.0 |
Receptor, Epidermal Growth Factor/metabolism | 2 | 0.0 |
Immunoglobulin G/immunology | 9 | 2.0 |
Lymphocyte Count/drug effects | 2 | 5.0 |
Monocytes/physiology | 6 | 5.0 |
Muromonab-CD3/pharmacology | 2 | 2.0 |
T-Lymphocytes/cytology | 6 | 6.0 |
Blood/immunology | 4 | 30.0 |
Immune System/*physiopathology | 2 | 13.0 |
Immunoglobulins/blood | 5 | 5.0 |
Incidence | 2 | 0.0 |
*Leukapheresis | 2 | 5.0 |
Postoperative Complications | 2 | 1.0 |
Postoperative Period | 2 | 0.0 |
Hematopoietic Stem Cells | 2 | 3.0 |
Megakaryocytes | 2 | 18.0 |
Antibodies, Monoclonal/diagnostic use | 60 | 7.0 |
Receptors, Retinoic Acid/genetics | 2 | 2.0 |
Biological Response Modifiers/*pharmacology | 2 | 10.0 |
Membrane Glycoproteins/biosynthesis | 2 | 1.0 |
Calcium Signaling | 2 | 2.0 |
Major Histocompatibility Complex | 10 | 4.0 |
Receptors, Antigen, T-Cell, alpha-beta | 5 | 13.0 |
Superantigens/*immunology | 7 | 8.0 |
Thymus Gland/cytology/*immunology | 4 | 12.0 |
Flow Cytometry/methods | 12 | 4.0 |
Antigens, CD3/*metabolism | 11 | 22.0 |
Antigens, Differentiation, T-Lymphocyte/metabolism | 14 | 12.0 |
Phosphatidylinositols/metabolism | 8 | 7.0 |
Lymphoma, T-Cell/*complications/pathology | 2 | 66.0 |
Thrombocytopenia/*etiology | 2 | 12.0 |
*Gene Deletion | 2 | 0.0 |
Lymphocyte Function-Associated Antigen-1/immunology | 7 | 25.0 |
Antigens, CD45/metabolism | 8 | 9.0 |
Microscopy, Electron, Scanning | 2 | 0.0 |
Bone Marrow Cells/*immunology/pathology | 3 | 50.0 |
Mast Cells/*immunology/pathology | 3 | 75.0 |
Crystallography, X-Ray | 4 | 0.0 |
Oxygen/metabolism | 2 | 0.0 |
Antigens, CD/*physiology | 41 | 13.0 |
Cell Aggregation | 7 | 6.0 |
Lymphocytes/*physiology | 5 | 6.0 |
Membrane Glycoproteins/*physiology | 18 | 6.0 |
Swine/*immunology | 3 | 9.0 |
Lymphoma, T-Cell/immunology/*pathology | 2 | 33.0 |
Cell Communication | 24 | 8.0 |
Cytokines/metabolism | 4 | 0.0 |
Intercellular Adhesion Molecule-1/metabolism | 6 | 3.0 |
Lymphocyte Function-Associated Antigen-1/metabolism | 4 | 8.0 |
T-Lymphocytes/*physiology | 59 | 20.0 |
Herpesvirus 2, Saimiriine/*immunology | 2 | 50.0 |
Receptors, Antigen, T-Cell/physiology | 31 | 22.0 |
Receptors, Antigen, T-Cell/*immunology | 42 | 23.0 |
Antigens, CD34/*immunology | 3 | 4.0 |
T-Lymphocytes/immunology/pathology | 5 | 8.0 |
DNA/analysis | 7 | 0.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Killer Cells, Natural/pathology | 3 | 10.0 |
Necrosis | 2 | 0.0 |
Colitis, Ulcerative/*immunology | 2 | 5.0 |
Crohn Disease/*immunology | 2 | 5.0 |
Immunity, Mucosal | 6 | 8.0 |
Intestinal Mucosa/immunology | 2 | 3.0 |
T-Lymphocyte Subsets/*physiology | 4 | 13.0 |
Inositol 1,4,5-Trisphosphate/metabolism | 2 | 3.0 |
Lectins/pharmacology | 3 | 8.0 |
Quinones/pharmacology | 10 | 7.0 |
Subcellular Fractions/immunology | 2 | 15.0 |
T-Lymphocytes/drug effects/immunology/*physiology | 2 | 20.0 |
Adjuvants, Immunologic/physiology | 3 | 6.0 |
Antigens, CD28/physiology | 8 | 9.0 |
Interferon Type II/*biosynthesis/genetics | 4 | 19.0 |
Promoter Regions (Genetics)/immunology | 2 | 2.0 |
T-Lymphocyte Subsets/*immunology/*metabolism | 2 | 7.0 |
Antigens, Surface/*analysis | 15 | 7.0 |
Antigens/immunology | 11 | 7.0 |
Antigens, CD58/*metabolism | 4 | 66.0 |
Macaca fascicularis | 3 | 1.0 |
Papio | 7 | 4.0 |
Receptors, Fc/metabolism | 3 | 6.0 |
Biological Response Modifiers/therapeutic use | 2 | 12.0 |
HTLV-I Infections/*complications | 2 | 50.0 |
Leukemic Infiltration | 2 | 15.0 |
Quality of Life | 2 | 1.0 |
Clone Cells/immunology | 14 | 9.0 |
Granulocytes/immunology | 4 | 7.0 |
T-Lymphocytes, Cytotoxic/*immunology | 30 | 5.0 |
DNA-Binding Proteins/physiology | 2 | 0.0 |
Ionomycin/pharmacology | 17 | 7.0 |
Transcription Factors/physiology | 2 | 0.0 |
1-Phosphatidylinositol 3-Kinase/physiology | 2 | 1.0 |
Antigens, CD29/*physiology | 2 | 9.0 |
Antigens, CD44/physiology | 2 | 9.0 |
Cell Movement | 12 | 1.0 |
Fibronectins/*metabolism | 2 | 2.0 |
Alleles | 3 | 0.0 |
Exons | 6 | 0.0 |
Family Health | 2 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Haplotypes | 3 | 0.0 |
Immunomagnetic Separation | 4 | 3.0 |
Peptides/chemical synthesis | 3 | 10.0 |
Antigen-Antibody Complex/metabolism | 3 | 5.0 |
Dose-Response Relationship, Drug | 17 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology | 30 | 3.0 |
Cell Transformation, Viral | 7 | 2.0 |
Chimera/immunology | 2 | 16.0 |
Disease Models, Animal | 4 | 0.0 |
Macaca nemestrina | 4 | 12.0 |
Immunoglobulins, Fab/immunology | 8 | 7.0 |
Protein-Tyrosine Kinase/metabolism/*physiology | 3 | 11.0 |
T-Lymphocytes/*enzymology/immunology | 3 | 13.0 |
src Homology Domains/immunology | 3 | 11.0 |
Receptor-CD3 Complex, Antigen, T-Cell/physiology | 7 | 25.0 |
Antigens, CD/biosynthesis/genetics | 3 | 8.0 |
Antigens, CD28/*metabolism | 6 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis/genetics | 2 | 20.0 |
Apoptosis/*physiology | 6 | 0.0 |
Cell Division/drug effects/physiology | 3 | 1.0 |
Histocompatibility Antigens Class I/*metabolism | 3 | 3.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/*physiology | 2 | 20.0 |
Receptor Cross-Talk | 4 | 10.0 |
Signal Transduction/*physiology | 12 | 1.0 |
Antigens, CD14 | 2 | 0.0 |
CD4-Positive T-Lymphocytes | 3 | 1.0 |
Hypereosinophilic Syndrome/*pathology | 2 | 66.0 |
Hematopoietic Stem Cells/immunology | 6 | 7.0 |
Lymphoid Tissue/cytology | 2 | 9.0 |
Bone Marrow Cells/pathology | 2 | 3.0 |
Proto-Oncogene Protein c-kit/genetics | 2 | 5.0 |
Carbohydrate Conformation | 5 | 4.0 |
Carbohydrate Sequence | 7 | 2.0 |
T-Lymphocytes/cytology/*immunology/*metabolism | 2 | 16.0 |
Antigens, CD18/metabolism | 2 | 4.0 |
Breast Neoplasms/*immunology/pathology | 2 | 8.0 |
Antigens, CD2/immunology/*metabolism/physiology | 2 | 100.0 |
Enzyme Activation/immunology | 5 | 3.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
Protein-Tyrosine-Phosphatase/metabolism | 2 | 1.0 |
Antigens, CD95/immunology/metabolism | 2 | 15.0 |
Apoptosis/*drug effects | 3 | 0.0 |
Thymus Gland/cytology | 11 | 11.0 |
*Hematopoietic Stem Cell Transplantation | 6 | 1.0 |
Lymphocyte Depletion | 12 | 7.0 |
Transplantation, Autologous | 7 | 1.0 |
Cesarean Section | 2 | 3.0 |
Pregnancy | 28 | 0.0 |
Antigens, CD/*biosynthesis | 9 | 4.0 |
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 6 | 9.0 |
Immunoglobulin M/biosynthesis | 5 | 5.0 |
Receptors, Antigen, T-Cell/genetics | 16 | 19.0 |
Tumor Markers, Biological/*immunology | 2 | 8.0 |
Antigens, CD56/*metabolism | 2 | 14.0 |
Herpesvirus 4, Human/isolation & purification | 3 | 5.0 |
Tumor Virus Infections/complications | 2 | 9.0 |
Antigen-Presenting Cells/*immunology | 15 | 10.0 |
Blood Donors | 4 | 1.0 |
HLA-D Antigens/*immunology | 3 | 5.0 |
T-Lymphocytes/drug effects/*immunology | 15 | 10.0 |
Receptors, Immunologic/*genetics/immunology | 2 | 15.0 |
Cell Adhesion/immunology | 16 | 9.0 |
Cell Culture Techniques | 7 | 1.0 |
Integrins/*metabolism | 3 | 2.0 |
Interleukin-2/immunology | 9 | 8.0 |
Protein Kinase C/metabolism | 7 | 1.0 |
Antigens, CD8/analysis/immunology | 3 | 33.0 |
Killer Cells, Natural/*chemistry | 2 | 28.0 |
Tumor Cells, Cultured/immunology | 9 | 10.0 |
Antigens, CD2/*immunology/metabolism | 3 | 100.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Binding Sites/immunology | 2 | 3.0 |
B-Lymphocytes/immunology/pathology | 3 | 6.0 |
Cytogenetics | 3 | 3.0 |
DNA Primers/genetics | 4 | 0.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 10 | 12.0 |
*Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 2 | 33.0 |
Killer Cells, Natural/immunology/pathology | 3 | 20.0 |
Lymphoma/*genetics/*immunology/pathology | 2 | 100.0 |
Antigens, CD30/*analysis | 2 | 10.0 |
Antigens, Neoplasm/immunology | 6 | 4.0 |
Cell Separation/*methods | 10 | 7.0 |
Immunotherapy/methods | 2 | 2.0 |
Prospective Studies | 14 | 0.0 |
Killer Cells, Natural/*drug effects | 4 | 13.0 |
Antigens, CD7/*analysis | 4 | 16.0 |
Electrophoresis, Gel, Two-Dimensional | 8 | 2.0 |
Antigens, CD4 | 5 | 6.0 |
Cytokines/*immunology | 2 | 2.0 |
Antigens, CD3/*analysis | 8 | 26.0 |
Immune System/*physiology | 3 | 4.0 |
Antibodies, Monoclonal/*therapeutic use | 4 | 1.0 |
Cytotoxicity, Immunologic/drug effects | 7 | 5.0 |
Immunotherapy, Adoptive | 3 | 4.0 |
Neoplasms/immunology/*therapy | 4 | 7.0 |
Protein Precursors/*pharmacology | 2 | 10.0 |
Thymosin/*analogs & derivatives/pharmacology | 2 | 25.0 |
Solubility | 25 | 1.0 |
*Cell Fusion | 2 | 5.0 |
Culture Media, Serum-Free | 5 | 1.0 |
Hybridomas/*physiology | 2 | 100.0 |
Leukemia, Lymphocytic, Acute/*pathology | 2 | 10.0 |
Protein Structure, Secondary | 6 | 0.0 |
src Homology Domains | 5 | 0.0 |
Langerhans Cells/*pathology | 2 | 15.0 |
Autoimmune Diseases/*immunology | 3 | 1.0 |
Lupus Erythematosus, Systemic/*immunology | 3 | 2.0 |
Antigens, CD34/analysis | 3 | 0.0 |
Blast Crisis | 2 | 5.0 |
Proto-Oncogene Protein c-kit/analysis | 2 | 4.0 |
Antigens, CD2/*chemistry/metabolism | 5 | 83.0 |
Cell Adhesion Molecules/chemistry | 2 | 14.0 |
*Killer Cells, Natural | 3 | 13.0 |
Neoplasm Staging | 5 | 0.0 |
Antigens, CD2/chemistry/metabolism | 2 | 66.0 |
Escherichia coli/genetics | 4 | 0.0 |
Nuclear Magnetic Resonance, Biomolecular | 2 | 1.0 |
Leukemia, Myeloid/*genetics/immunology | 2 | 33.0 |
Oligonucleotide Probes | 6 | 0.0 |
*Transcription, Genetic | 7 | 0.0 |
Antigens, CD28/genetics/*physiology | 2 | 33.0 |
Leukocytes, Mononuclear/metabolism | 5 | 2.0 |
Response Elements/immunology | 2 | 12.0 |
T-Lymphocyte Subsets/*immunology/metabolism | 4 | 8.0 |
HLA Antigens/immunology | 11 | 6.0 |
*Lymphocyte Depletion | 8 | 10.0 |
*Lymphocyte Transfusion | 3 | 11.0 |
Antigens, CD11/blood | 2 | 28.0 |
HLA-DR Antigens/drug effects | 2 | 33.0 |
Lymphocytes/immunology | 12 | 3.0 |
Neutrophils/immunology | 3 | 1.0 |
DNA, Viral/genetics | 4 | 2.0 |
Lymphoma, T-Cell/*pathology | 4 | 28.0 |
Nose Neoplasms/*pathology | 2 | 40.0 |
Antigens, CD29/analysis | 2 | 9.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 2 | 1.0 |
Leukapheresis/*methods | 2 | 14.0 |
Time | 2 | 6.0 |
Receptors, Antigen, T-Cell/*metabolism | 9 | 6.0 |
Antigens, CD/*analysis/genetics | 3 | 12.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
CD8-Positive T-Lymphocytes/*immunology | 9 | 2.0 |
Herpesviridae Infections/*complications | 2 | 28.0 |
*Kidney Transplantation | 5 | 1.0 |
Cell Adhesion Molecules/immunology | 9 | 13.0 |
Antigens, CD/chemistry | 3 | 20.0 |
Antigens, CD2/chemistry | 2 | 100.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
*Receptors, Lipoprotein | 2 | 1.0 |
Recombinant Proteins/chemistry/metabolism | 4 | 0.0 |
Autoimmune Diseases/*immunology/pathology | 2 | 12.0 |
CD8-Positive T-Lymphocytes/cytology/*immunology | 2 | 7.0 |
Epithelial Cells/cytology/immunology | 2 | 15.0 |
Killer Cells, Lymphokine-Activated/immunology | 11 | 16.0 |
Transforming Growth Factor beta/*pharmacology | 2 | 0.0 |
Cell Division/immunology | 21 | 7.0 |
*Cell Division | 3 | 1.0 |
Endometrium/*cytology | 3 | 15.0 |
Lymphocytes/*cytology/immunology | 3 | 30.0 |
Receptors, IgG/analysis | 6 | 9.0 |
T-Lymphocytes/*immunology/*metabolism | 2 | 6.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
*T-Lymphocytes | 5 | 10.0 |
Crohn Disease/*immunology/pathology | 2 | 15.0 |
*Transplantation Conditioning | 2 | 8.0 |
Histocytochemistry | 14 | 2.0 |
Aorta | 2 | 1.0 |
*Genes, MHC Class I | 2 | 0.0 |
Graft Rejection/immunology | 2 | 3.0 |
Immunologic Capping | 10 | 20.0 |
*Major Histocompatibility Complex | 4 | 1.0 |
Recombinant Proteins/immunology | 7 | 2.0 |
*Receptors, G-Protein-Coupled | 2 | 0.0 |
T-Lymphocytes/drug effects/*immunology/metabolism | 8 | 34.0 |
Antigens, CD11/analysis | 2 | 6.0 |
Kidney Transplantation/immunology | 2 | 3.0 |
Killer Cells, Natural/drug effects/immunology | 3 | 9.0 |
*Ploidies | 4 | 5.0 |
Cell Adhesion Molecules/biosynthesis | 7 | 8.0 |
Injections, Intravenous | 6 | 0.0 |
Lymphocyte Subsets/drug effects | 3 | 15.0 |
Recombinant Proteins/administration & dosage | 2 | 2.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/*metabolism | 2 | 2.0 |
Human T-lymphotropic virus 1/*physiology | 2 | 7.0 |
Monocytes/*metabolism | 2 | 0.0 |
Protein Kinase C/antagonists & inhibitors | 6 | 4.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 3 | 1.0 |
Antigens, Differentiation/analysis | 28 | 9.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 9 | 5.0 |
Neoplasm Proteins/*analysis | 5 | 1.0 |
Cell Size | 2 | 0.0 |
Molecular Conformation | 4 | 1.0 |
Antigens, Differentiation/pharmacology | 2 | 9.0 |
Binding, Competitive/immunology | 5 | 5.0 |
Intracellular Fluid/metabolism | 5 | 4.0 |
Mitogens/*pharmacology | 3 | 2.0 |
T-Lymphocytes/*immunology/ultrastructure | 3 | 20.0 |
Herpesvirus 4, Human/*isolation & purification | 5 | 13.0 |
Biological Markers/*analysis | 2 | 1.0 |
Case-Control Studies | 9 | 0.0 |
Logistic Models | 4 | 0.0 |
Reproducibility of Results | 5 | 0.0 |
Antigens, CD2/immunology/*metabolism | 5 | 100.0 |
Cell Polarity | 2 | 1.0 |
Cytoplasm | 2 | 3.0 |
Thymus Gland | 2 | 10.0 |
Calcium/blood | 2 | 0.0 |
Lymphocytes/*drug effects/immunology | 2 | 8.0 |
Antigens, CD45/immunology | 4 | 6.0 |
Membrane Glycoproteins/*chemistry | 2 | 6.0 |
*Semaphorins | 2 | 8.0 |
Signal Transduction/physiology | 5 | 0.0 |
Antigens, CD/blood | 7 | 2.0 |
Antigens, CD2/genetics/*immunology | 2 | 100.0 |
DNA Mutational Analysis | 5 | 0.0 |
Hydrocortisone/blood | 5 | 1.0 |
Immune Tolerance | 16 | 5.0 |
Drug Resistance | 3 | 0.0 |
Interleukin-4/*physiology | 2 | 4.0 |
Antigens, CD/genetics/*metabolism | 2 | 2.0 |
Biopsy, Needle | 5 | 1.0 |
Thyroid Gland/*immunology | 2 | 3.0 |
Aging/immunology | 4 | 7.0 |
B-Lymphocyte Subsets/*immunology | 2 | 2.0 |
Bone Marrow/immunology | 10 | 7.0 |
Antigens, CD2/pharmacology | 3 | 100.0 |
Antigens, CD28/pharmacology | 4 | 40.0 |
Allergens/*immunology | 4 | 5.0 |
Pollen/*immunology | 2 | 11.0 |
*Clonal Anergy | 3 | 10.0 |
HIV Infections/*immunology | 5 | 1.0 |
HIV-1/*immunology | 6 | 1.0 |
Homosexuality | 2 | 1.0 |
Predictive Value of Tests | 10 | 0.0 |
Cytotoxicity, Immunologic/immunology | 4 | 5.0 |
Down-Regulation/immunology | 4 | 4.0 |
Interferon Type II/immunology | 4 | 4.0 |
Mutagenesis, Site-Directed | 15 | 0.0 |
Surface Plasmon Resonance | 2 | 1.0 |
Tumor Necrosis Factor-alpha/immunology | 4 | 3.0 |
Antigens, CD3/*physiology | 6 | 35.0 |
*Cell Cycle Proteins | 2 | 0.0 |
Cricetulus | 4 | 0.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/physiology | 2 | 14.0 |
*Protein Processing, Post-Translational | 3 | 1.0 |
Killer Cells, Natural/*pathology/ultrastructure | 2 | 100.0 |
Disease Progression | 11 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
CD4-Positive T-Lymphocytes/*physiology | 10 | 12.0 |
Microscopy, Confocal | 4 | 0.0 |
Receptor-CD3 Complex, Antigen, T-Cell/*physiology | 3 | 13.0 |
Antigens, CD45 | 37 | 17.0 |
Body Mass Index | 2 | 0.0 |
Food | 2 | 1.0 |
Immunoglobulin G/blood | 2 | 0.0 |
Antigens, CD/*analysis/*biosynthesis | 2 | 40.0 |
Colony-Forming Units Assay | 9 | 1.0 |
Fibronectins/physiology | 4 | 11.0 |
Tyrosine | 2 | 1.0 |
Substance P/*pharmacology | 2 | 6.0 |
Granulocyte Colony-Stimulating Factor/*therapeutic use | 3 | 5.0 |
Cytokines/secretion | 3 | 3.0 |
Interleukin-2/physiology | 12 | 14.0 |
Blood Platelets/*metabolism | 2 | 0.0 |
Leukemia, Erythroblastic, Acute/metabolism | 2 | 11.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
Protein Binding/physiology | 3 | 1.0 |
Transcription, Genetic/genetics | 4 | 1.0 |
Cytoplasm/chemistry | 2 | 1.0 |
Cytoskeleton/*physiology | 2 | 5.0 |
Receptor Aggregation | 10 | 10.0 |
Receptors, Cell Surface/*physiology | 5 | 2.0 |
T-Lymphocytes/metabolism/*physiology | 3 | 23.0 |
src Homology Domains/physiology | 3 | 6.0 |
Bone Marrow Transplantation/*immunology | 7 | 5.0 |
Lymphocyte Function-Associated Antigen-1/*physiology | 12 | 29.0 |
Membrane Glycoproteins/metabolism | 8 | 1.0 |
Serine Endopeptidases/metabolism | 5 | 4.0 |
Image Processing, Computer-Assisted | 3 | 0.0 |
Keratinocytes/pathology | 2 | 8.0 |
Receptors, Immunologic/metabolism | 12 | 7.0 |
T-Lymphocytes, Helper-Inducer/immunology | 9 | 4.0 |
DNA, Neoplasm/genetics | 5 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 2 | 0.0 |
HL-60 Cells | 2 | 0.0 |
T-Lymphocytes/immunology/*physiology | 7 | 12.0 |
Antigens, CD8/*analysis | 7 | 10.0 |
*Herpesvirus 4, Human | 2 | 5.0 |
Antigens, CD34 | 18 | 2.0 |
*Protein Conformation | 6 | 2.0 |
Antigens, Neoplasm/analysis | 17 | 5.0 |
DNA, Viral/analysis | 7 | 2.0 |
Cell Adhesion/drug effects/*immunology | 2 | 50.0 |
Antigens, CD2/*pharmacology | 2 | 100.0 |
Antigens, CD3/pharmacology | 2 | 12.0 |
*Microtubule Proteins | 3 | 10.0 |
Serine/*metabolism | 2 | 2.0 |
T-Lymphocytes/*enzymology/*immunology | 4 | 40.0 |
Proteins/*metabolism | 3 | 0.0 |
Interleukin-2/metabolism | 11 | 7.0 |
Mitogens/physiology | 2 | 11.0 |
Recombinant Fusion Proteins/metabolism | 8 | 0.0 |
T-Lymphocytes/*drug effects/metabolism | 4 | 11.0 |
Interleukin-2/secretion | 12 | 16.0 |
Animals, Genetically Modified | 2 | 0.0 |
Dendritic Cells/immunology | 2 | 1.0 |
Rats, Inbred F344 | 3 | 0.0 |
Rats, Inbred Lew | 5 | 1.0 |
Histocompatibility Antigens Class II/analysis | 3 | 1.0 |
Immunoglobulin G/analysis | 4 | 1.0 |
Immunoglobulin M/analysis | 2 | 0.0 |
T-Lymphocytes/cytology/immunology | 3 | 4.0 |
Antigens, CD18/immunology | 2 | 11.0 |
Antigens, Neoplasm/*immunology | 4 | 2.0 |
Intercellular Adhesion Molecule-1/immunology | 3 | 7.0 |
Melanoma/immunology | 2 | 5.0 |
Receptors, Antigen, T-Cell, gamma-delta/*immunology | 5 | 10.0 |
Cell Adhesion Molecules/*analysis | 13 | 10.0 |
Intercellular Adhesion Molecule-1/analysis | 5 | 4.0 |
*Ultraviolet Rays | 2 | 0.0 |
Vascular Cell Adhesion Molecule-1/analysis | 2 | 5.0 |
Cell Compartmentation | 5 | 1.0 |
Cell Death/immunology | 2 | 6.0 |
Intestinal Mucosa/cytology/*immunology | 5 | 33.0 |
Fetal Blood/*cytology | 6 | 3.0 |
Hybridomas | 7 | 4.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis | 8 | 9.0 |
RNA, Messenger | 2 | 0.0 |
Cell Culture Techniques/*methods | 2 | 2.0 |
Hematopoietic Stem Cells/*cytology | 6 | 2.0 |
Animals, Newborn | 2 | 0.0 |
Graft Rejection/*immunology | 3 | 3.0 |
Macrophages/*immunology | 4 | 1.0 |
Transplantation, Heterologous/*immunology | 4 | 6.0 |
DNA | 4 | 0.0 |
RNA, Messenger/genetics | 34 | 1.0 |
Sequence Homology, Nucleic Acid | 6 | 0.0 |
Environmental Monitoring | 2 | 5.0 |
CD4-Positive T-Lymphocytes/metabolism | 2 | 1.0 |
Cyclosporine/*pharmacology | 3 | 2.0 |
*Lymphocyte Activation/drug effects | 18 | 16.0 |
RNA, Messenger/drug effects | 2 | 3.0 |
Signal Transduction/drug effects/immunology | 2 | 4.0 |
T-Lymphocytes/immunology/*metabolism | 10 | 10.0 |
Leukemia, Lymphocytic, Acute, L1/*immunology/pathology | 2 | 40.0 |
Lymphocytes, Tumor-Infiltrating/*immunology | 3 | 4.0 |
Melanoma/*immunology | 2 | 2.0 |
Chromosome Disorders | 12 | 3.0 |
HLA Antigens/analysis | 6 | 2.0 |
Cell Membrane | 2 | 3.0 |
Antigens, CD95/*immunology | 4 | 11.0 |
DNA/genetics | 13 | 0.0 |
Phosphorylation/drug effects | 2 | 0.0 |
Receptors, Interleukin-2/physiology | 17 | 36.0 |
Serine/metabolism | 2 | 0.0 |
Thymidine/metabolism | 4 | 1.0 |
*Antigens, CD2 | 2 | 100.0 |
*Immune Tolerance | 4 | 2.0 |
Receptor-CD3 Complex, Antigen, T-Cell | 2 | 66.0 |
T-Lymphocytes/cytology/immunology/metabolism | 2 | 10.0 |
Transfection/immunology | 2 | 4.0 |
Fetal Blood/cytology/*immunology | 2 | 10.0 |
Stromal Cells/cytology/immunology | 2 | 33.0 |
*Chromosomes, Human, Pair 11 | 3 | 0.0 |
Disease-Free Survival | 4 | 0.0 |
*Proto-Oncogenes | 3 | 0.0 |
Recurrence | 6 | 0.0 |
*Transcription Factors | 3 | 0.0 |
Zinc Fingers | 2 | 0.0 |
Macrophages/pathology | 4 | 3.0 |
T-Lymphocytes/pathology | 8 | 7.0 |
Acylation | 2 | 2.0 |
Antigens, CD2/genetics/metabolism | 2 | 66.0 |
Membrane Lipids/*metabolism | 2 | 6.0 |
Receptors, Interleukin-2/genetics/metabolism | 3 | 21.0 |
Recombinant Proteins/metabolism | 8 | 0.0 |
Antibodies, Monoclonal/*administration & dosage/immunology | 2 | 25.0 |
Lymphocyte Function-Associated Antigen-1/*immunology | 5 | 25.0 |
Binding Sites, Antibody | 13 | 4.0 |
Escherichia coli | 2 | 0.0 |
Genes, Immunoglobulin | 10 | 5.0 |
Recombinant Proteins/biosynthesis/chemistry | 2 | 2.0 |
Restriction Mapping | 11 | 0.0 |
Leukapheresis | 2 | 1.0 |
*Cell Line | 3 | 6.0 |
Leukocytes, Mononuclear/cytology/immunology | 3 | 6.0 |
*Antigen Presentation | 2 | 1.0 |
Interleukin-2/*biosynthesis | 11 | 7.0 |
Stimulation, Chemical | 6 | 1.0 |
Up-Regulation/drug effects | 2 | 0.0 |
*Antigens, Nuclear | 2 | 1.0 |
Chromatography, Affinity | 10 | 1.0 |
*DNA Helicases | 2 | 0.0 |
Epitopes/metabolism | 2 | 3.0 |
Introns | 2 | 0.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
T-Lymphocytes/cytology/*immunology | 15 | 11.0 |
Formaldehyde | 3 | 3.0 |
*Immunoenzyme Techniques | 5 | 4.0 |
Paraffin Embedding | 2 | 0.0 |
Tissue Fixation | 3 | 3.0 |
Graft Survival/immunology | 3 | 5.0 |
*Immunosuppression | 2 | 2.0 |
Rats, Inbred Strains | 2 | 0.0 |
Receptors, Antigen, T-Cell, alpha-beta/metabolism | 2 | 6.0 |
Receptors, Immunologic/*metabolism | 24 | 13.0 |
Cell Adhesion/*physiology | 3 | 2.0 |
Cell Membrane/metabolism | 9 | 0.0 |
Surface Properties | 2 | 1.0 |
Cytoplasmic Granules/*immunology | 3 | 42.0 |
Lymphocyte Subsets/immunology | 8 | 5.0 |
Antigens, CD/immunology/metabolism | 5 | 9.0 |
Erythropoiesis | 3 | 3.0 |
Immunoglobulins/immunology/metabolism | 2 | 33.0 |
Antibody-Dependent Cell Cytotoxicity | 8 | 9.0 |
Culture Media, Conditioned | 4 | 1.0 |
Cytokines/*physiology | 2 | 1.0 |
Interleukin-12/pharmacology | 3 | 6.0 |
Ionophores/pharmacology | 3 | 2.0 |
Antigens, CD20 | 7 | 9.0 |
B-Lymphocytes/immunology/metabolism | 2 | 3.0 |
Killer Cells, Natural/immunology/metabolism | 3 | 10.0 |
Lymphocytes/immunology/*metabolism | 3 | 12.0 |
T-Lymphocytes/immunology/metabolism | 7 | 5.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Oxidation-Reduction | 3 | 0.0 |
Common Variable Immunodeficiency/*immunology | 2 | 13.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 2 | 1.0 |
Fluorescent Antibody Technique | 68 | 2.0 |
Receptors, Immunologic/*physiology | 96 | 56.0 |
Antibodies, Monoclonal/chemistry/pharmacology | 2 | 40.0 |
Cercopithecus aethiops | 6 | 0.0 |
Lymphocyte Function-Associated Antigen-1/analysis | 6 | 14.0 |
Transforming Growth Factor beta/analysis | 2 | 4.0 |
Killer Cells, Natural/chemistry/*pathology | 3 | 50.0 |
Lymphocytes/*pathology | 2 | 4.0 |
Antigens, CD40/immunology | 2 | 3.0 |
Immunoglobulins, Heavy-Chain/genetics | 6 | 3.0 |
T-Lymphocytes/metabolism | 7 | 2.0 |
Antibodies/immunology | 2 | 0.0 |
B-Lymphocytes/*cytology | 3 | 4.0 |
Mice, Inbred Strains | 5 | 0.0 |
Chromosomes, Human, Pair 1 | 3 | 1.0 |
Antigens, Surface/analysis/immunology | 3 | 18.0 |
Neoplasm Proteins/analysis/immunology | 2 | 28.0 |
Nuclear Proteins/analysis/immunology | 2 | 40.0 |
Transcription Factors/analysis/immunology | 2 | 50.0 |
*Heart Transplantation | 2 | 2.0 |
Receptors, Antigen, T-Cell, alpha-beta/immunology | 6 | 9.0 |
Cytokines/analysis | 3 | 4.0 |
Cytokines/physiology | 3 | 1.0 |
Antibody Formation | 8 | 1.0 |
*Antigens, CD34 | 3 | 4.0 |
Immunoglobulin M/metabolism | 3 | 3.0 |
Tumor Necrosis Factor-alpha/*physiology | 2 | 0.0 |
T-Lymphocytes/immunology/*pathology | 7 | 18.0 |
Leukemia, T-Cell/*pathology | 3 | 30.0 |
Hypersensitivity, Delayed | 2 | 3.0 |
Anthropometry | 2 | 0.0 |
1-Phosphatidylinositol 3-Kinase | 2 | 1.0 |
Proteins/metabolism | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics | 2 | 0.0 |
Genes, Reporter | 2 | 0.0 |
*Virus Replication | 3 | 1.0 |
Fibroblasts/cytology | 2 | 0.0 |
Histocompatibility Antigens Class I/physiology | 3 | 13.0 |
Receptors, Lymphocyte Homing/physiology | 2 | 9.0 |
Diffusion | 2 | 2.0 |
Fluorescence | 3 | 1.0 |
Immunoglobulin G/metabolism | 3 | 1.0 |
*Cell Transformation, Viral | 4 | 2.0 |
Mice, Nude | 5 | 0.0 |
Neoplasm Transplantation | 5 | 0.0 |
Transplantation, Heterologous | 4 | 0.0 |
Life Tables | 4 | 2.0 |
Antigens, CD/biosynthesis/blood | 2 | 22.0 |
Antigens, CD3/*blood | 2 | 25.0 |
Immunosuppressive Agents/pharmacology | 5 | 3.0 |
Interleukin-2/*biosynthesis/blood | 2 | 40.0 |
Lymphocyte Activation/drug effects/physiology | 2 | 13.0 |
*Gene Rearrangement, T-Lymphocyte | 2 | 4.0 |
Receptors, Antigen, T-Cell, gamma-delta/genetics | 4 | 16.0 |
*HIV-1 | 2 | 0.0 |
Histocompatibility Antigens Class I | 3 | 27.0 |
*Immunity, Natural | 2 | 3.0 |
T-Lymphocytes/*immunology/virology | 2 | 11.0 |
Cell Cycle/physiology | 2 | 0.0 |
Transcription Factors/metabolism | 3 | 0.0 |
Cell Adhesion/*drug effects | 4 | 7.0 |
Endothelium, Vascular/*cytology | 4 | 2.0 |
Lymphocytes/*cytology | 4 | 12.0 |
Cell Adhesion Molecules/metabolism | 6 | 2.0 |
Epithelial Cells | 9 | 1.0 |
Antigens, CD/analysis/*immunology | 5 | 12.0 |
Antigens, CD3/analysis/*immunology | 2 | 33.0 |
Antigens, CD4/analysis/immunology | 2 | 16.0 |
Antigens, Differentiation, B-Lymphocyte/analysis/immunology | 4 | 40.0 |
Creatinine/blood | 3 | 0.0 |
Immunosuppressive Agents/*therapeutic use | 2 | 1.0 |
Kidney Transplantation/*immunology | 5 | 2.0 |
Antigens, Surface/analysis | 38 | 9.0 |
Fluorescent Antibody Technique, Direct | 3 | 2.0 |
Mast Cells/immunology/pathology | 2 | 66.0 |
Bone Marrow Transplantation | 6 | 2.0 |
Cell Nucleus/ultrastructure | 5 | 4.0 |
Etoposide/administration & dosage | 6 | 5.0 |
Herpesvirus 4, Human | 7 | 5.0 |
Neoplasm Invasiveness | 6 | 0.0 |
Leukemia/*classification/immunology/pathology | 2 | 66.0 |
Antigen-Antibody Reactions | 24 | 6.0 |
Calcimycin/pharmacology | 13 | 5.0 |
Centrifugation/methods | 2 | 14.0 |
Centrifugation, Density Gradient | 5 | 1.0 |
Histamine Release/drug effects | 3 | 12.0 |
Administration, Oral | 2 | 0.0 |
Cell Adhesion Molecules/*blood | 2 | 3.0 |
T-Lymphocyte Subsets/drug effects | 2 | 10.0 |
Tumor Stem Cells/*immunology | 2 | 8.0 |
Pregnancy Trimester, First | 8 | 2.0 |
T-Lymphocytes/classification/cytology/*immunology | 2 | 25.0 |
Tetanus Toxoid/immunology | 4 | 5.0 |
Antigens, CD45/*blood | 2 | 20.0 |
Fetal Blood/*immunology | 2 | 2.0 |
Interleukin-2/biosynthesis/genetics | 3 | 7.0 |
Immunologic Deficiency Syndromes/immunology | 3 | 17.0 |
Mitogens/immunology | 2 | 7.0 |
Chromosomes, Human, Pair 17 | 2 | 0.0 |
Chromosomes, Human, Pair 9 | 4 | 2.0 |
Leukemia/*pathology | 4 | 9.0 |
Killer Cells, Natural/immunology/*metabolism | 3 | 10.0 |
*Antibody Formation | 2 | 2.0 |
Cycloheximide/pharmacology | 8 | 1.0 |
Immunoglobulin E/*biosynthesis | 5 | 10.0 |
Interleukin-4/immunology | 3 | 5.0 |
Cell Differentiation/physiology | 3 | 0.0 |
Leukocytes, Mononuclear/cytology | 4 | 8.0 |
Antibodies, Anti-Idiotypic/immunology | 2 | 5.0 |
Immunoglobulin M/immunology | 3 | 2.0 |
Tonsil/cytology | 3 | 3.0 |
Drug Carriers | 2 | 1.0 |
Temperature | 6 | 0.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 24 | 10.0 |
Protein Binding/immunology | 2 | 1.0 |
T-Lymphocytes/*drug effects | 5 | 7.0 |
Gene Transfer Techniques | 3 | 0.0 |
Genetic Markers | 2 | 0.0 |
Hematopoietic Stem Cells/chemistry/*cytology | 2 | 20.0 |
Cell Adhesion Molecules/*chemistry | 3 | 18.0 |
Immunosuppressive Agents/therapeutic use | 3 | 1.0 |
Longitudinal Studies | 2 | 0.0 |
Concanavalin A/pharmacology | 10 | 4.0 |
T-Lymphocytes/drug effects/immunology/*metabolism | 4 | 17.0 |
Transforming Growth Factor beta/*physiology | 3 | 2.0 |
HIV-1/*physiology | 5 | 1.0 |
Virus Replication/*drug effects | 2 | 1.0 |
Biological Transport | 3 | 0.0 |
Callithrix | 2 | 2.0 |
Dactinomycin/pharmacology | 6 | 1.0 |
Cytokines/immunology | 2 | 1.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 7 | 1.0 |
Aorta/cytology | 2 | 2.0 |
Cell Death/drug effects | 2 | 1.0 |
Guinea Pigs | 2 | 0.0 |
Interleukin-1/metabolism | 3 | 1.0 |
Killer Cells, Natural/cytology | 3 | 12.0 |
Leukocytes, Mononuclear/*cytology | 2 | 9.0 |
Macrophages/cytology | 2 | 2.0 |
Antigens, CD8/*metabolism | 2 | 6.0 |
Radiation Dosage | 2 | 2.0 |
Down-Regulation/*drug effects | 2 | 3.0 |
Antigens, CD45/*metabolism | 3 | 9.0 |
Cytoplasm/*metabolism | 2 | 1.0 |
Lymphoma, T-Cell | 3 | 15.0 |
Leukocytes, Mononuclear/*metabolism | 5 | 3.0 |
Receptors, Immunologic/biosynthesis | 6 | 20.0 |
Antineoplastic Agents/*therapeutic use | 3 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
Superantigens/immunology | 2 | 4.0 |
Graft vs Host Disease/*prevention & control | 5 | 18.0 |
Embryonic Development/*physiology | 2 | 14.0 |
Chemotaxis, Leukocyte | 2 | 1.0 |
HLA-DR Antigens/immunology | 6 | 2.0 |
Macrophage-1 Antigen/analysis | 2 | 4.0 |
Leukemia, Myelocytic, Acute/*genetics/pathology | 2 | 6.0 |
Protein-Tyrosine Kinase/*analysis | 3 | 9.0 |
Tyrosine/*metabolism | 5 | 1.0 |
Culture Techniques/methods | 3 | 5.0 |
Interleukin-12/*pharmacology | 4 | 8.0 |
Histocompatibility Antigens Class I/*immunology | 4 | 3.0 |
Major Histocompatibility Complex/*immunology | 2 | 5.0 |
Tetrachlorodibenzodioxin/*toxicity | 2 | 4.0 |
Killer Cells, Lymphokine-Activated/*immunology | 12 | 17.0 |
Leukemia/*immunology/pathology | 2 | 18.0 |
Epitopes | 27 | 3.0 |
Isoantigens/immunology | 4 | 4.0 |
Antigens, Differentiation | 7 | 9.0 |
Interleukins/biosynthesis | 2 | 4.0 |
Antibodies, Monoclonal/chemistry | 2 | 2.0 |
T-Lymphocyte Subsets/*metabolism | 3 | 10.0 |
Antigens, CD3/*genetics | 2 | 20.0 |
*Bone Marrow Cells | 16 | 6.0 |
Hematopoietic Stem Cells/*immunology | 8 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/*chemistry | 3 | 60.0 |
Cell Membrane/ultrastructure | 2 | 4.0 |
Glycosylphosphatidylinositols | 5 | 9.0 |
Macromolecular Substances | 14 | 0.0 |
Precipitin Tests | 30 | 1.0 |
T-Lymphocytes/*ultrastructure | 2 | 33.0 |
Blood Cell Count | 6 | 2.0 |
Recombination, Genetic | 6 | 0.0 |
B-Lymphocyte Subsets | 2 | 16.0 |
Tonsil/immunology | 3 | 4.0 |
Antigens, Surface/blood | 4 | 18.0 |
Graft Rejection/*prevention & control | 3 | 7.0 |
Graft vs Host Disease/prevention & control | 3 | 5.0 |
Antigens, CD4/*analysis | 10 | 6.0 |
T-Lymphocyte Subsets/immunology/*pathology | 2 | 18.0 |
Adjuvants, Immunologic/*pharmacology | 3 | 1.0 |
Antigens, CD4/metabolism | 9 | 2.0 |
Antigens, CD8/metabolism | 6 | 11.0 |
Dermatitis, Contact/immunology | 2 | 20.0 |
Indicators and Reagents | 3 | 1.0 |
Recombinant Fusion Proteins/pharmacology | 2 | 2.0 |
Protein Folding | 7 | 1.0 |
Endocytosis | 10 | 2.0 |
Lipopolysaccharides/immunology | 2 | 1.0 |
Phytohemagglutinins/immunology | 5 | 10.0 |
Pokeweed Mitogens/immunology | 2 | 15.0 |
Antigens, CD3/blood | 2 | 6.0 |
Immunologic Memory/*immunology | 2 | 6.0 |
Immunotherapy | 9 | 2.0 |
Killer Cells, Natural/*classification/*immunology | 2 | 100.0 |
Leukemia, Myeloid/*immunology/pathology | 2 | 14.0 |
Enterotoxins/pharmacology | 3 | 4.0 |
Receptors, Antigen, T-Cell, alpha-beta/*metabolism | 3 | 23.0 |
Antigens, CD/immunology/*metabolism | 3 | 6.0 |
Membrane Glycoproteins/*metabolism | 8 | 1.0 |
Antigens, CD7/metabolism | 2 | 40.0 |
Stem Cells/immunology | 2 | 6.0 |
B-Lymphocyte Subsets/immunology | 2 | 5.0 |
Hematopoietic Stem Cells/*cytology/immunology | 5 | 6.0 |
*Leukocyte Count | 4 | 6.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Spleen/immunology | 7 | 3.0 |
Receptors, Antigen, T-Cell/*genetics | 13 | 13.0 |
Epitopes/*immunology | 6 | 2.0 |
Genes, fos | 2 | 1.0 |
Cell Movement/immunology | 4 | 4.0 |
Endothelium, Vascular/metabolism | 4 | 1.0 |
Epithelium/metabolism | 3 | 0.0 |
Oligosaccharides/*chemistry | 2 | 11.0 |
Scattering, Radiation | 2 | 1.0 |
Neutrophils/*immunology | 2 | 1.0 |
Sex Characteristics | 2 | 0.0 |
T-Lymphocytes/classification | 5 | 15.0 |
Antibodies, Monoclonal/immunology/pharmacology | 2 | 2.0 |
Antigens, CD/immunology/physiology | 3 | 18.0 |
Killer Cells, Lymphokine-Activated/*cytology | 3 | 50.0 |
Killer Cells, Natural/*drug effects/immunology | 3 | 11.0 |
Lymphoma, Non-Hodgkin/pathology | 2 | 14.0 |
Protease Inhibitors/pharmacology | 2 | 0.0 |
Antigens, CD2/genetics/immunology | 3 | 100.0 |
Cell Movement/physiology | 4 | 1.0 |
Skin/*immunology | 2 | 1.0 |
Ethers, Cyclic/pharmacology | 2 | 5.0 |
Okadaic Acid | 2 | 4.0 |
Hydrogen-Ion Concentration | 6 | 0.0 |
Interleukin-4/*biosynthesis | 2 | 3.0 |
Bone Marrow/*immunology/pathology | 2 | 11.0 |
Thymus Gland/immunology/*pathology | 2 | 25.0 |
Antigens, CD8/genetics | 4 | 26.0 |
Antigens, Differentiation, T-Lymphocyte/genetics | 3 | 9.0 |
*Homeodomain Proteins | 2 | 0.0 |
Proteins/genetics | 4 | 0.0 |
Membrane Glycoproteins/*analysis/immunology | 2 | 15.0 |
Antigen-Presenting Cells | 2 | 10.0 |
Cell Adhesion Molecules | 7 | 13.0 |
Computer Simulation | 2 | 0.0 |
Drug Design | 2 | 0.0 |
Leukemia, Erythroblastic, Acute | 3 | 3.0 |
Melanoma | 2 | 2.0 |
Immunity, Cellular/drug effects | 3 | 5.0 |
Cell Communication/*immunology | 4 | 9.0 |
Phorbol Esters/pharmacology | 6 | 5.0 |
Umbilical Veins | 6 | 1.0 |
Decidua/*immunology | 4 | 22.0 |
Receptors, Complement/analysis | 2 | 3.0 |
Langerhans Cells/pathology | 3 | 17.0 |
Antigens, Surface/physiology | 14 | 35.0 |
Lymphocyte Function-Associated Antigen-1/physiology | 9 | 20.0 |
Interleukins/*biosynthesis | 2 | 8.0 |
Killer Cells, Natural/*cytology/immunology | 3 | 42.0 |
Antibodies, Monoclonal/therapeutic use | 2 | 1.0 |
*Aging | 2 | 1.0 |
India/ethnology | 2 | 2.0 |
Recombinant Proteins/biosynthesis/metabolism | 3 | 1.0 |
Regulatory Sequences, Nucleic Acid | 4 | 0.0 |
Bronchoalveolar Lavage Fluid/*immunology | 2 | 6.0 |
Antigens, Bacterial/*immunology | 3 | 2.0 |
Epithelium/immunology | 2 | 1.0 |
Keratinocytes/immunology | 2 | 8.0 |
*Antigens, Neoplasm | 4 | 2.0 |
*Glycoproteins | 2 | 0.0 |
Immunoglobulins/analysis | 5 | 2.0 |
Proto-Oncogene Proteins c-bcl-2 | 3 | 1.0 |
Graft Survival | 6 | 1.0 |
Splenic Neoplasms/pathology | 2 | 66.0 |
Interleukin-1/*physiology | 5 | 5.0 |
Electrophoresis, Agar Gel | 4 | 0.0 |
Lipid Bilayers | 3 | 7.0 |
Liposomes | 2 | 0.0 |
Leukocytes, Mononuclear/*immunology | 4 | 2.0 |
Antigens, CD2/genetics | 3 | 50.0 |
Fibronectins/metabolism | 2 | 1.0 |
Lymphocytes/drug effects/*immunology | 2 | 4.0 |
Recombinant Proteins/*pharmacology | 2 | 2.0 |
Lymphokines/*secretion | 2 | 4.0 |
Hemophilia A/complications/*immunology | 2 | 14.0 |
Histocompatibility Antigens Class II/immunology | 8 | 4.0 |
T-Lymphocytes/*cytology/immunology | 13 | 27.0 |
Thymus Gland/*cytology | 7 | 13.0 |
Electron Spin Resonance Spectroscopy | 2 | 0.0 |
Magnetics | 7 | 8.0 |
Arthritis, Rheumatoid/*immunology/pathology | 2 | 6.0 |
Enterotoxins/*pharmacology | 4 | 7.0 |
Antigens, Ly/*genetics | 3 | 30.0 |
*Genes, Structural | 3 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Lymphocyte Activation/genetics/immunology | 2 | 15.0 |
Antigens, CD4/genetics | 2 | 3.0 |
Leukemia, T-Cell, Acute/*immunology | 4 | 36.0 |
Interleukins/immunology | 3 | 17.0 |
Antigens, CD/*analysis/metabolism | 2 | 28.0 |
Microspheres | 3 | 1.0 |
Bone Marrow/*immunology | 4 | 6.0 |
*Lectins | 5 | 2.0 |
Hematopoietic Stem Cells/immunology/*physiology | 2 | 13.0 |
T-Lymphocytes/physiology | 9 | 7.0 |
Thymus Gland/*cytology/immunology | 2 | 10.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
*Endocytosis | 3 | 1.0 |
T-Lymphocytes | 13 | 5.0 |
Recombinant Proteins/therapeutic use | 3 | 0.0 |
Circular Dichroism | 2 | 0.0 |
Sulfhydryl Compounds/metabolism | 3 | 8.0 |
Antigens, Differentiation/immunology/physiology | 2 | 50.0 |
Cell Adhesion/drug effects/*physiology | 2 | 6.0 |
Cell Adhesion Molecules/physiology | 8 | 8.0 |
Antigens, Surface/*immunology | 31 | 19.0 |
Daunorubicin/administration & dosage | 2 | 5.0 |
Leukemia, T-Cell | 3 | 8.0 |
Receptors, Antigen, T-Cell, alpha-beta/*genetics | 2 | 2.0 |
B-Lymphocytes/cytology | 5 | 6.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
*Gene Expression Regulation, Viral | 4 | 1.0 |
Hemagglutinins, Viral/immunology | 3 | 30.0 |
Interleukin-2/pharmacology/secretion | 2 | 25.0 |
*Cloning, Molecular | 4 | 1.0 |
Interleukin-3/pharmacology | 3 | 1.0 |
Oligodeoxyribonucleotides | 4 | 0.0 |
*Transfection | 3 | 1.0 |
Neoplasms/*immunology | 4 | 3.0 |
Antigens, CD58 | 95 | 65.0 |
Epitopes/immunology | 18 | 3.0 |
Membrane Glycoproteins/physiology | 16 | 10.0 |
Leukemia, Nonlymphocytic, Acute/*genetics | 2 | 25.0 |
Tumor Markers, Biological | 3 | 0.0 |
Tumor Stem Cells/chemistry/*pathology | 2 | 40.0 |
*Rosette Formation | 18 | 41.0 |
Immunoglobulin G/biosynthesis | 6 | 3.0 |
Trisomy | 4 | 3.0 |
Receptors, IgE/metabolism | 2 | 6.0 |
Tumor Necrosis Factor-alpha/*secretion | 2 | 2.0 |
Antigens, CD4/*metabolism | 2 | 0.0 |
B-Lymphocytes | 3 | 1.0 |
Burkitt Lymphoma | 2 | 2.0 |
Calcium/analysis | 2 | 6.0 |
Cross Reactions/*immunology | 2 | 20.0 |
Antigen-Presenting Cells/*physiology | 6 | 17.0 |
B-Lymphocytes/physiology | 2 | 3.0 |
Lymphocyte Cooperation | 7 | 9.0 |
Antigens, Surface/*physiology | 24 | 37.0 |
B-Lymphocytes/*metabolism | 2 | 1.0 |
Interleukin-1/biosynthesis | 3 | 1.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 5 | 0.0 |
Integrins/*immunology | 2 | 12.0 |
Bone Marrow/immunology/pathology | 3 | 8.0 |
Antigens, CD/genetics/*immunology | 2 | 5.0 |
Antigens, CD59 | 7 | 3.0 |
Membrane Proteins/*physiology | 2 | 1.0 |
Phosphotyrosine | 13 | 4.0 |
Receptors, Antigen, T-Cell/*immunology/*physiology | 2 | 100.0 |
Tyrosine/analogs & derivatives/metabolism | 9 | 7.0 |
Antilymphocyte Serum/*administration & dosage | 2 | 66.0 |
Immunoglobulin G/*pharmacology | 2 | 12.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
Phytohemagglutinins | 10 | 10.0 |
Receptors, Antigen, T-Cell/*physiology | 46 | 28.0 |
Ki-67 Antigen | 2 | 0.0 |
Receptors, Antigen, T-Cell/analysis/genetics | 3 | 60.0 |
Cyclic AMP/*metabolism | 2 | 0.0 |
T-Lymphocytes/metabolism/*pathology | 2 | 14.0 |
Cyclic AMP/analysis | 2 | 8.0 |
Phosphatidic Acids/metabolism | 2 | 11.0 |
Phosphotransferases/metabolism | 2 | 4.0 |
Cell Communication/physiology | 4 | 4.0 |
Evaluation Studies | 3 | 0.0 |
Bronchoalveolar Lavage Fluid/cytology | 3 | 2.0 |
Neutrophils/enzymology | 2 | 2.0 |
Antigens, CD40 | 5 | 8.0 |
HTLV-I Infections/*immunology | 3 | 18.0 |
HTLV-II Infections/*immunology | 3 | 50.0 |
Integrins/immunology | 4 | 19.0 |
Up-Regulation/immunology | 3 | 1.0 |
Fluorescent Dyes | 5 | 1.0 |
Antigens, Surface/*metabolism | 7 | 11.0 |
CD4-Positive T-Lymphocytes/cytology/*immunology | 3 | 4.0 |
L-Selectin | 5 | 7.0 |
Antigens, CD3/analysis/physiology | 3 | 75.0 |
Antigens, CD4/physiology | 3 | 3.0 |
Receptors, Antigen, T-Cell, alpha-beta/*analysis | 2 | 8.0 |
Receptors, Antigen, T-Cell, gamma-delta/*analysis | 3 | 7.0 |
Horses | 5 | 3.0 |
T-Lymphocytes, Cytotoxic/immunology/*metabolism | 2 | 33.0 |
Leukemia, Myelocytic, Acute/*immunology | 6 | 17.0 |
*Phenotype | 2 | 0.0 |
Lymphocyte Activation/drug effects/immunology | 3 | 5.0 |
Signal Transduction/*drug effects | 4 | 1.0 |
Gestational Age | 6 | 0.0 |
Receptors, Antigen, T-Cell/biosynthesis | 5 | 35.0 |
Mice, Inbred A | 2 | 3.0 |
Receptors, Antigen, T-Cell/*analysis | 14 | 26.0 |
Receptors, Interferon/*analysis | 2 | 50.0 |
Injections, Intralymphatic | 2 | 28.0 |
Neoplasm Metastasis | 3 | 0.0 |
Lymphocyte Function-Associated Antigen-1/analysis/genetics | 2 | 100.0 |
Membrane Glycoproteins/analysis/genetics | 2 | 28.0 |
*Protein Structure, Secondary | 6 | 4.0 |
Cell Membrane/enzymology | 2 | 0.0 |
Egtazic Acid/pharmacology | 5 | 4.0 |
Colon/immunology | 2 | 9.0 |
Vascular Cell Adhesion Molecule-1 | 5 | 6.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics | 4 | 5.0 |
Epstein-Barr Virus Nuclear Antigens | 2 | 4.0 |
RNA, Messenger/isolation & purification | 2 | 2.0 |
Receptors, Interleukin-2/*biosynthesis/genetics | 2 | 33.0 |
Up-Regulation/genetics | 2 | 2.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Clonal Anergy/*immunology | 2 | 8.0 |
Orthomyxoviridae/immunology | 2 | 10.0 |
Receptors, Interleukin-2/biosynthesis | 9 | 8.0 |
Membrane Fluidity | 3 | 8.0 |
Antigens, CD29 | 14 | 22.0 |
Fixatives | 3 | 4.0 |
Lymphoma/*immunology/pathology | 3 | 27.0 |
Antigens, Differentiation, T-Lymphocyte/*physiology | 87 | 58.0 |
Intercellular Adhesion Molecule-1/physiology | 3 | 12.0 |
CD4-Positive T-Lymphocytes/*cytology | 2 | 4.0 |
Interleukin-2/*immunology | 3 | 4.0 |
Tumor Necrosis Factor-alpha/metabolism | 4 | 0.0 |
Histocompatibility Antigens Class I/immunology | 9 | 8.0 |
Lymphocyte Activation/drug effects/*immunology | 3 | 7.0 |
Lymphokines/biosynthesis | 3 | 2.0 |
*Chromosomes, Human, Pair 1 | 7 | 1.0 |
Mice, Inbred C3H | 2 | 0.0 |
*Genes, ras | 2 | 0.0 |
Interphase | 4 | 2.0 |
Killer Cells, Natural/*physiology | 11 | 23.0 |
Methylation | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology | 82 | 34.0 |
T-Lymphocytes/chemistry/*immunology | 2 | 14.0 |
Recombinant Proteins | 14 | 1.0 |
Interferon Type II/metabolism | 6 | 2.0 |
Antigens, CD7 | 19 | 16.0 |
Antigens, CD3/genetics | 2 | 14.0 |
Interleukin-2/*physiology | 11 | 15.0 |
Antigens, Differentiation, T-Lymphocyte/physiology | 34 | 41.0 |
Capillaries | 2 | 3.0 |
Membrane Glycoproteins/biosynthesis/genetics | 3 | 6.0 |
Endothelium, Vascular/cytology/*immunology | 4 | 12.0 |
DNA Primers/chemistry | 3 | 0.0 |
Antibody Specificity/immunology | 2 | 3.0 |
T-Lymphocyte Subsets/pathology | 3 | 10.0 |
Hematopoietic Cell Growth Factors/pharmacology | 2 | 2.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 2 | 0.0 |
Stem Cell Factor | 3 | 3.0 |
*Immunity, Cellular | 8 | 6.0 |
Transforming Growth Factor beta/*immunology | 2 | 25.0 |
Antigens, Bacterial/immunology | 2 | 1.0 |
Infant, Newborn/*immunology | 3 | 12.0 |
Mycobacterium/immunology | 2 | 15.0 |
Immunologic Deficiency Syndromes/*immunology | 3 | 8.0 |
Interferon-gamma, Recombinant/pharmacology | 5 | 3.0 |
Monocytes/drug effects | 2 | 3.0 |
Thalidomide/*pharmacology | 2 | 11.0 |
Antigens, CD45/*immunology | 3 | 9.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Genes, myc | 2 | 0.0 |
Immunotherapy/*methods | 2 | 1.0 |
Lymphocytes, Tumor-Infiltrating/immunology | 2 | 5.0 |
Thymus Gland/*immunology | 7 | 12.0 |
Cell Adhesion Molecules/*immunology | 10 | 19.0 |
Epithelium/physiology | 2 | 2.0 |
Interleukin-4/metabolism | 3 | 3.0 |
Antigens, Differentiation/physiology | 13 | 24.0 |
Isoantigens/*immunology | 4 | 5.0 |
Endothelium, Vascular/*physiology | 2 | 1.0 |
Polyenes/pharmacology | 2 | 7.0 |
Sirolimus | 2 | 4.0 |
T-Lymphocyte Subsets/*drug effects/immunology | 2 | 9.0 |
Alkaloids/pharmacology | 3 | 2.0 |
Calcium/physiology | 23 | 11.0 |
Cytochalasin B/pharmacology | 4 | 4.0 |
Staurosporine | 3 | 3.0 |
Tyrosine/*analogs & derivatives/metabolism | 2 | 3.0 |
Receptors, Very Late Antigen/*physiology | 3 | 25.0 |
Endothelium, Vascular/cytology | 4 | 1.0 |
Hematopoiesis | 6 | 2.0 |
Whole-Body Irradiation | 3 | 3.0 |
Interleukin-6/metabolism | 2 | 0.0 |
CD4-Positive T-Lymphocytes/cytology | 2 | 2.0 |
Lymphocytes/*metabolism | 6 | 3.0 |
Antigens, Differentiation, B-Lymphocyte/*analysis | 4 | 6.0 |
Chimeric Proteins | 2 | 2.0 |
Antigens, Differentiation, B-Lymphocyte/biosynthesis | 2 | 6.0 |
B-Lymphocytes/cytology/*immunology | 4 | 5.0 |
Interleukin-2 | 3 | 17.0 |
Receptors, Immunologic/*immunology | 63 | 54.0 |
*Blood Donors | 2 | 1.0 |
Variation (Genetics) | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis/immunology | 7 | 46.0 |
Receptors, Immunologic/*analysis/immunology | 2 | 66.0 |
Antigens, CD4/*genetics | 2 | 3.0 |
Antigens, CD8/*genetics | 2 | 25.0 |
Antigens, CD8/*physiology | 2 | 22.0 |
Second Messenger Systems | 3 | 3.0 |
*Antigens, Differentiation | 5 | 5.0 |
Cell Adhesion Molecules/*physiology | 18 | 16.0 |
Leukocytes/*physiology | 2 | 3.0 |
Antigens, Differentiation, T-Lymphocyte/chemistry/*metabolism | 2 | 66.0 |
Receptors, Immunologic/chemistry/*metabolism | 2 | 15.0 |
Antigens, CD/*analysis/blood | 2 | 14.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Interleukins/*pharmacology | 6 | 8.0 |
*CD4-CD8 Ratio | 2 | 3.0 |
Pokeweed Mitogens/pharmacology | 7 | 8.0 |
T-Lymphocyte Subsets/drug effects/immunology | 3 | 15.0 |
Leukocyte Count/drug effects | 3 | 2.0 |
Macaca mulatta | 3 | 0.0 |
Antigens, CD44 | 4 | 2.0 |
Carrier Proteins/*immunology | 3 | 6.0 |
Receptors, Lymphocyte Homing/*immunology | 2 | 10.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 46 | 22.0 |
Intercellular Adhesion Molecule-1 | 50 | 21.0 |
Protein Kinase C/*physiology | 3 | 3.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 8 | 2.0 |
Leukemia, Myelocytic, Acute/immunology/pathology | 2 | 28.0 |
Lymphoma, T-Cell/genetics/immunology/*pathology | 2 | 40.0 |
Multiple Myeloma/*immunology | 3 | 8.0 |
Cell Aggregation/immunology | 3 | 15.0 |
Lymphocyte Activation/radiation effects | 2 | 18.0 |
T-Lymphocytes/*immunology/radiation effects | 2 | 18.0 |
Antigens, Differentiation, T-Lymphocyte/genetics/*metabolism | 3 | 37.0 |
Cell Membrane/immunology/ultrastructure | 3 | 25.0 |
Receptors, Immunologic/genetics/*metabolism | 2 | 5.0 |
Antigens, CD55 | 4 | 2.0 |
Hemoglobinuria, Paroxysmal/*immunology | 2 | 9.0 |
Human T-lymphotropic virus 1/genetics | 3 | 20.0 |
HLA-DR Antigens/*analysis | 7 | 4.0 |
Tretinoin/pharmacology | 2 | 0.0 |
Fetus/*immunology | 2 | 4.0 |
Organ Culture Techniques | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/*physiology | 3 | 8.0 |
Interferon Type II/physiology | 2 | 2.0 |
Receptors, Immunologic/physiology | 39 | 34.0 |
Antigens, CD8/immunology | 6 | 7.0 |
Endothelium, Vascular/immunology/*physiology | 2 | 28.0 |
Erythrocytes/immunology/*physiology | 2 | 40.0 |
Antigens, Differentiation, T-Lymphocyte/immunology/*physiology | 11 | 52.0 |
Peptide Mapping | 6 | 1.0 |
Receptors, Immunologic/immunology/*physiology | 7 | 87.0 |
Trypsin/metabolism | 2 | 1.0 |
Lymphocyte Activation/physiology | 4 | 5.0 |
Antigens, CD/analysis/physiology | 2 | 16.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/physiology | 5 | 41.0 |
Lymphocyte Function-Associated Antigen-1/analysis/physiology | 2 | 100.0 |
Antigen-Presenting Cells/physiology | 8 | 14.0 |
Receptors, Immunologic/analysis/*physiology | 3 | 60.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Liver/*immunology | 2 | 5.0 |
CD4-Positive T-Lymphocytes/pathology | 3 | 4.0 |
Membrane Glycoproteins/immunology | 12 | 6.0 |
Antigens, Differentiation, T-Lymphocyte | 57 | 21.0 |
Receptors, Antigen, T-Cell/*biosynthesis | 2 | 33.0 |
Receptors, IgG | 22 | 15.0 |
*Cell Differentiation | 2 | 0.0 |
Culture Media | 2 | 0.0 |
Cell Adhesion/*immunology | 2 | 10.0 |
T-Lymphocytes/*cytology | 14 | 15.0 |
Chickens/*immunology | 2 | 22.0 |
Histocompatibility Antigens Class I/analysis | 4 | 4.0 |
Iron/*pharmacology | 3 | 20.0 |
DNA Probes | 6 | 0.0 |
Keratin/analysis | 2 | 0.0 |
Antigens, CD5 | 16 | 6.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/*immunology | 13 | 59.0 |
Immunotoxins/*pharmacology | 4 | 9.0 |
*N-Glycosyl Hydrolases | 2 | 3.0 |
Plant Proteins/*pharmacology | 2 | 10.0 |
Receptors, Immunologic/analysis/*immunology | 4 | 57.0 |
Langerhans Cells/*immunology | 2 | 5.0 |
Macrophages/immunology | 6 | 2.0 |
Mice, Inbred DBA | 2 | 0.0 |
Antigens, CD/*pharmacology | 2 | 18.0 |
Antigens, Differentiation, T-Lymphocyte/genetics/*physiology | 4 | 44.0 |
Receptors, Immunologic/genetics/*physiology | 4 | 23.0 |
Interleukin-6/*pharmacology | 3 | 1.0 |
Neoplasms/immunology | 2 | 3.0 |
Receptors, Immunologic/immunology/*metabolism | 3 | 25.0 |
T-Lymphocyte Subsets/drug effects/*immunology | 2 | 7.0 |
Carrier Proteins/analysis | 4 | 4.0 |
DNA Nucleotidylexotransferase/analysis | 2 | 10.0 |
Antigens, Differentiation, B-Lymphocyte/*immunology | 3 | 4.0 |
Enterotoxins/*immunology | 6 | 8.0 |
Antigens, CD95 | 2 | 5.0 |
Mice, Mutant Strains | 2 | 0.0 |
Receptors, Antigen, T-Cell/genetics/*physiology | 2 | 40.0 |
HLA Antigens/*immunology | 6 | 2.0 |
Multiple Sclerosis/*immunology | 4 | 3.0 |
*Antibodies, Monoclonal | 3 | 1.0 |
Interleukin-2/genetics/secretion | 2 | 28.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Menopause/*immunology | 2 | 40.0 |
Cattle/*immunology | 2 | 11.0 |
Flow Cytometry/veterinary | 2 | 28.0 |
Depression, Chemical | 5 | 2.0 |
Hematopoietic Stem Cells/*physiology | 3 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/immunology | 5 | 38.0 |
Receptors, Immunologic/analysis/immunology | 5 | 83.0 |
Cytoskeleton/physiology | 3 | 3.0 |
Protein Kinases/*metabolism | 2 | 0.0 |
Interleukin-2/*genetics | 5 | 7.0 |
Cell Differentiation/genetics | 2 | 0.0 |
Gene Expression/*genetics | 3 | 2.0 |
Receptors, Interleukin-2/genetics | 2 | 5.0 |
Bone Marrow/*pathology | 3 | 2.0 |
Antigens, CD/analysis/immunology | 4 | 8.0 |
Cell Adhesion Molecules/analysis/immunology | 2 | 28.0 |
Kidney Transplantation/*immunology/pathology | 2 | 11.0 |
Lymphocyte Subsets/pathology | 2 | 8.0 |
HTLV-I Antibodies/analysis | 2 | 22.0 |
Skin/*immunology/pathology | 2 | 10.0 |
Skin Neoplasms/*immunology/pathology | 2 | 10.0 |
Cytokines/*secretion | 3 | 5.0 |
T-Lymphocytes/*microbiology | 2 | 6.0 |
Macaca/*immunology | 2 | 25.0 |
Cytotoxicity, Immunologic/physiology | 2 | 40.0 |
Interleukin-12 | 4 | 23.0 |
Interleukins/*physiology | 4 | 13.0 |
Magnetic Resonance Spectroscopy/methods | 2 | 4.0 |
Receptors, Immunologic/*chemistry | 2 | 25.0 |
Antibodies | 3 | 0.0 |
Oligonucleotides, Antisense | 2 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/genetics/*immunology | 7 | 38.0 |
Cyclic AMP/metabolism | 4 | 0.0 |
Receptors, Immunologic/genetics/*immunology | 5 | 50.0 |
Hybridomas/immunology | 4 | 3.0 |
Receptors, Very Late Antigen/metabolism | 2 | 18.0 |
Hybridomas/*immunology | 2 | 6.0 |
Antigens, Differentiation, T-Lymphocyte/immunology/*metabolism | 6 | 46.0 |
GTPase-Activating Proteins | 2 | 1.0 |
Inositol Phosphates/metabolism | 11 | 8.0 |
Isoenzymes/*metabolism | 2 | 0.0 |
Phospholipase C/*metabolism | 3 | 2.0 |
Membrane Glycoproteins/*analysis | 5 | 3.0 |
Antigens, CD/analysis/*metabolism | 4 | 26.0 |
Calcium/*physiology | 6 | 5.0 |
*Inversion, Chromosome | 2 | 2.0 |
Killer Cells, Lymphokine-Activated/physiology | 2 | 33.0 |
Plastics | 5 | 15.0 |
Forskolin/pharmacology | 4 | 1.0 |
Peroxidase/*analysis | 3 | 15.0 |
Interferon Type II/*pharmacology | 3 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 2 | 0.0 |
Cervix Neoplasms/*immunology | 2 | 10.0 |
Interleukin-2/analysis | 3 | 7.0 |
Mitogens | 4 | 5.0 |
Receptors, Transferrin/biosynthesis | 2 | 40.0 |
Antigen-Presenting Cells/immunology/physiology | 2 | 50.0 |
Models, Biological | 8 | 0.0 |
T-Lymphocytes/cytology/*immunology/metabolism | 2 | 9.0 |
Antigens, CD57 | 6 | 9.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis/*physiology | 2 | 50.0 |
Membrane Glycoproteins/genetics | 3 | 1.0 |
Cytoplasm/ultrastructure | 2 | 3.0 |
Neoplasms, Second Primary/*pathology | 2 | 28.0 |
Receptors, Immunologic/analysis/physiology | 2 | 100.0 |
T-Lymphocytes/cytology/*physiology | 3 | 18.0 |
Interleukin-2/biosynthesis/pharmacology | 3 | 14.0 |
Antigens, Differentiation, T-Lymphocyte/*genetics | 6 | 11.0 |
Erythrocytes/*physiology | 2 | 4.0 |
RNA, Viral/genetics/isolation & purification | 2 | 10.0 |
Receptors, Immunologic/*genetics | 7 | 5.0 |
Interleukin-3/*pharmacology | 2 | 1.0 |
Lymphocyte Subsets/*pathology | 2 | 20.0 |
Lymphoproliferative Disorders/*pathology | 2 | 50.0 |
Integrins/analysis | 2 | 4.0 |
Infectious Mononucleosis/*immunology | 2 | 10.0 |
Antigens, Differentiation, T-Lymphocyte/chemistry/*physiology | 2 | 33.0 |
Receptors, Immunologic/chemistry/*physiology | 2 | 33.0 |
Monocytes/*physiology | 3 | 1.0 |
Antigens, Differentiation, Myelomonocytic/*biosynthesis | 2 | 13.0 |
Antigens, CD11 | 13 | 16.0 |
Antigens, Differentiation, Myelomonocytic/*analysis | 4 | 3.0 |
*Hematopoiesis | 2 | 1.0 |
Genes, Structural | 11 | 1.0 |
Chromosome Aberrations/pathology | 2 | 22.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/*metabolism | 3 | 37.0 |
Membrane Glycoproteins/analysis/*metabolism | 2 | 28.0 |
Receptors, Immunologic/analysis/*metabolism | 2 | 40.0 |
Antigens, CD26 | 5 | 18.0 |
Protein Kinase C/antagonists & inhibitors/*metabolism | 3 | 3.0 |
Inversion, Chromosome | 2 | 3.0 |
T-Lymphocytes/cytology/drug effects/*immunology | 2 | 7.0 |
Antigens, CD4/immunology | 8 | 4.0 |
Oligodeoxyribonucleotides/chemistry | 5 | 2.0 |
Blast Crisis/genetics/*pathology | 2 | 28.0 |
Leukemia, Myeloid, Chronic/genetics/*pathology | 2 | 15.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
Immunologic Techniques | 12 | 3.0 |
Polymers/pharmacology | 2 | 9.0 |
Radioligand Assay | 3 | 0.0 |
Antigens, CD80 | 3 | 9.0 |
Antigens, CD28 | 32 | 22.0 |
Immunoglobulins/*blood | 2 | 6.0 |
Receptors, Immunologic | 12 | 33.0 |
NF-kappa B/physiology | 2 | 2.0 |
Antigens, CD18 | 16 | 17.0 |
Histocompatibility Antigens Class II/metabolism | 2 | 2.0 |
Magnesium/pharmacology | 4 | 3.0 |
Cell Adhesion Molecules/*analysis/physiology | 3 | 33.0 |
Leukemia, T-Cell/*immunology | 6 | 35.0 |
Lymphoma | 2 | 5.0 |
Interleukin-6/secretion | 2 | 3.0 |
*Neoplasm Proteins | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis/genetics/*physiology | 2 | 50.0 |
Antigens, CD1 | 7 | 7.0 |
Histocompatibility Antigens Class I/biosynthesis | 3 | 6.0 |
Bucladesine/pharmacology | 3 | 1.0 |
*Signal Transduction/drug effects | 2 | 2.0 |
Cytochalasin D/pharmacology | 2 | 2.0 |
Receptors, Retinoic Acid | 2 | 3.0 |
Philadelphia Chromosome | 2 | 4.0 |
T-Lymphocytes/*drug effects/immunology/metabolism | 3 | 21.0 |
Tumor Stem Cells/pathology | 2 | 6.0 |
Antigens, CD/immunology/*physiology | 4 | 12.0 |
Edetic Acid/pharmacology | 5 | 2.0 |
Autoantigens/immunology | 2 | 1.0 |
E-Selectin | 2 | 2.0 |
Receptors, Antigen, T-Cell, alpha-beta/analysis | 3 | 6.0 |
*Epitopes | 3 | 2.0 |
Hepatitis C/*immunology/pathology/therapy | 2 | 100.0 |
Interleukins/pharmacology | 2 | 2.0 |
Receptors, Leukocyte-Adhesion/*analysis | 4 | 44.0 |
Autoimmune Diseases/*drug therapy/immunology | 2 | 28.0 |
Lymph Nodes/immunology/pathology | 3 | 7.0 |
Quality Control | 2 | 1.0 |
HLA-D Antigens/analysis | 3 | 5.0 |
Leukemia, Myeloid/*immunology | 2 | 5.0 |
Antibodies, Neoplasm/*immunology | 2 | 8.0 |
Cell Fusion | 4 | 1.0 |
Leucine/analogs & derivatives/pharmacology | 2 | 11.0 |
Antigens, CD/*analysis/physiology | 3 | 25.0 |
Hemolysis | 2 | 0.0 |
Leukemia/*immunology | 2 | 5.0 |
*Genotype | 2 | 0.0 |
Antigens, CD4/*physiology | 2 | 1.0 |
Lymphocytes, Tumor-Infiltrating/*physiology | 2 | 25.0 |
Leukocytes, Mononuclear/pathology | 2 | 10.0 |
Lymphocyte Function-Associated Antigen-1/*analysis | 4 | 50.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism/*physiology | 4 | 100.0 |
T-Lymphocyte Subsets/cytology/*immunology | 3 | 12.0 |
*Chromosomes, Human, Pair 8 | 3 | 1.0 |
Antigens, CD/*immunology/metabolism | 5 | 15.0 |
Membrane Glycoproteins/*immunology/metabolism | 2 | 12.0 |
Receptors, Fc/physiology | 6 | 24.0 |
Antigens, CD45/*analysis | 3 | 6.0 |
Staphylococcus aureus/*immunology | 3 | 3.0 |
Receptors, Cell Surface/*analysis | 2 | 1.0 |
Receptors, Tumor Necrosis Factor | 3 | 1.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 3 | 0.0 |
HIV-1/*genetics | 3 | 0.0 |
T-Lymphocytes/cytology/*microbiology | 2 | 40.0 |
*Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 3 | 11.0 |
Leukemia, Myeloid/*genetics | 2 | 1.0 |
Antigens, Thy-1 | 2 | 6.0 |
Iodoacetamide/pharmacology | 2 | 12.0 |
*Chromosomes, Human, Pair 9 | 2 | 0.0 |
Lymphoma, Non-Hodgkin/*genetics/pathology | 2 | 14.0 |
Plasma Cells/*pathology | 2 | 10.0 |
Cytosol/enzymology | 2 | 1.0 |
Phorbol 12,13-Dibutyrate/pharmacology | 5 | 8.0 |
Receptors, Interleukin-2/*analysis | 4 | 5.0 |
Receptors, Immunologic/genetics | 4 | 9.0 |
Antigens, CD/*immunology/physiology | 2 | 40.0 |
Proto-Oncogene Proteins/*analysis | 2 | 1.0 |
*Blood Transfusion | 2 | 1.0 |
Graft vs Host Disease/*immunology | 3 | 11.0 |
Immunity, Natural | 4 | 1.0 |
Receptors, Antigen, T-Cell/analysis/*immunology | 3 | 50.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase | 2 | 5.0 |
Histocompatibility Antigens/physiology | 3 | 37.0 |
Interleukin-1/physiology | 3 | 3.0 |
Interleukin-6/physiology | 2 | 3.0 |
Receptors, Fc/immunology | 5 | 11.0 |
Leukemia, Promyelocytic, Acute/genetics/*pathology | 2 | 66.0 |
Antilymphocyte Serum/*immunology | 2 | 15.0 |
Interferon Type II/genetics/secretion | 2 | 50.0 |
Lymphokines/immunology | 2 | 10.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*biosynthesis/genetics | 2 | 50.0 |
Tumor Cells, Cultured/*immunology | 6 | 27.0 |
Calcium/pharmacology | 2 | 0.0 |
Actins/metabolism | 2 | 0.0 |
Cytoskeleton/ultrastructure | 3 | 12.0 |
Arachidonic Acids/metabolism | 2 | 5.0 |
Bone Marrow Examination | 4 | 11.0 |
Immunoglobulins, Surface/*analysis | 2 | 25.0 |
Enhancer Elements (Genetics) | 3 | 0.0 |
Liver/embryology | 2 | 6.0 |
Antigens, CD/analysis/*genetics | 2 | 13.0 |
Antigens, CD15 | 2 | 6.0 |
Cell Separation/methods | 10 | 6.0 |
Carrier Proteins/*genetics | 4 | 0.0 |
*Chromosomes, Human, Pair 15 | 2 | 0.0 |
*Chromosomes, Human, Pair 17 | 2 | 0.0 |
Antigens, CD/analysis/metabolism | 2 | 14.0 |
Lymphokines/*biosynthesis | 2 | 0.0 |
Fusion Proteins, bcr-abl/genetics | 2 | 4.0 |
Lymph Nodes/*pathology | 3 | 3.0 |
Ethylmaleimide/pharmacology | 2 | 3.0 |
Multiple Myeloma/*immunology/*pathology | 2 | 33.0 |
Histocompatibility Antigens/analysis | 8 | 13.0 |
Glycoproteins/immunology | 3 | 3.0 |
Histocompatibility Antigens/*analysis | 5 | 10.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/*physiology | 3 | 33.0 |
Receptors, Antigen, T-Cell/analysis/*physiology | 2 | 100.0 |
Leukemia, Nonlymphocytic, Acute/*immunology | 2 | 25.0 |
Frozen Sections | 4 | 4.0 |
Leukemia/*diagnosis/drug therapy/genetics | 2 | 100.0 |
Phosphatidylinositols/*physiology | 3 | 18.0 |
Tumor Cells, Cultured/immunology/pathology | 2 | 11.0 |
Hematopoietic Stem Cells/cytology | 4 | 4.0 |
*Immunologic Techniques | 2 | 6.0 |
Leukemia, T-Cell/pathology/surgery/*therapy | 2 | 100.0 |
*Magnetics | 5 | 20.0 |
Tumor Cells, Cultured/pathology | 2 | 3.0 |
Interleukin-2/administration & dosage/blood/*therapeutic use | 2 | 66.0 |
Clone Cells/drug effects | 2 | 8.0 |
Peptides/pharmacology | 2 | 1.0 |
Receptors, IgE | 6 | 9.0 |
Virus Replication | 4 | 0.0 |
Receptors, Antigen, T-Cell | 8 | 20.0 |
Phospholipase C/*physiology | 2 | 16.0 |
*Integrin alpha Chains | 2 | 7.0 |
Chromosome Deletion | 2 | 0.0 |
Chromosomes, Human, Pair 7 | 2 | 1.0 |
Genome, Viral | 2 | 1.0 |
Monocytes/pathology | 2 | 5.0 |
Thymus Gland/*embryology | 2 | 50.0 |
Radioimmunoassay | 4 | 0.0 |
beta 2-Microglobulin/*immunology | 2 | 8.0 |
Leukemia, Lymphocytic/*immunology/pathology | 2 | 18.0 |
*Lymphocyte Culture Test, Mixed | 2 | 3.0 |
Antigens, Differentiation/*physiology | 17 | 19.0 |
Receptors, Fc/*physiology | 7 | 19.0 |
Receptors, Immunologic/immunology/metabolism | 2 | 28.0 |
Antigens, Differentiation, T-Lymphocyte/chemistry/*immunology | 2 | 50.0 |
Recombinant Fusion Proteins | 4 | 1.0 |
Chloroquine/pharmacology | 2 | 2.0 |
Alveolitis, Extrinsic Allergic/*immunology | 2 | 18.0 |
Occupational Exposure/*adverse effects | 2 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology/metabolism | 3 | 60.0 |
Receptors, Leukocyte-Adhesion/immunology | 3 | 25.0 |
Histocompatibility Antigens/*physiology | 4 | 33.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 4 | 2.0 |
Antigens, CD13 | 2 | 3.0 |
Genes, Immunoglobulin/genetics | 2 | 8.0 |
Receptors, Fc/analysis | 2 | 3.0 |
Hypersensitivity/*immunology | 2 | 4.0 |
Interleukin-2/biosynthesis/*physiology | 2 | 25.0 |
Nickel/*immunology | 2 | 28.0 |
Leukemia, Myelocytic, Acute/drug therapy/*immunology | 2 | 50.0 |
Azides/pharmacology | 3 | 12.0 |
Sodium Azide | 2 | 15.0 |
Thymus Gland/pathology | 2 | 8.0 |
Membrane Proteins/*analysis | 2 | 2.0 |
Antigenic Modulation | 3 | 37.0 |
Receptors, Antigen, T-Cell/*immunology/metabolism | 2 | 22.0 |
Antigens, Surface/immunology/*physiology | 4 | 40.0 |
Cell Adhesion Molecules/immunology/*physiology | 2 | 20.0 |
Receptors, Fc/*analysis | 4 | 18.0 |
Mites/*immunology | 2 | 4.0 |
HIV Seropositivity/immunology | 2 | 2.0 |
Half-Life | 2 | 0.0 |
Protein-Tyrosine Kinase/physiology | 2 | 1.0 |
Antibodies, Monoclonal/*diagnostic use | 8 | 3.0 |
Neprilysin | 4 | 5.0 |
Lymphokines/physiology | 2 | 2.0 |
Cyclosporins/pharmacology | 5 | 13.0 |
Endothelium, Vascular/*immunology | 4 | 4.0 |
Antigens, Differentiation, B-Lymphocyte/immunology | 6 | 11.0 |
Membrane Glycoproteins/immunology/metabolism | 2 | 6.0 |
*Antibody-Dependent Cell Cytotoxicity | 3 | 6.0 |
Receptors, Fc/biosynthesis | 2 | 12.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis/physiology | 3 | 42.0 |
Receptors, Antigen, T-Cell, gamma-delta | 8 | 14.0 |
*Chromosomes, Human, Pair 7 | 2 | 0.0 |
Receptors, Antigen, T-Cell/immunology/*physiology | 3 | 37.0 |
T-Lymphocytes/immunology/metabolism/*physiology | 2 | 66.0 |
HLA-D Antigens/immunology | 4 | 10.0 |
Interleukin-2/*metabolism | 2 | 4.0 |
Glycoproteins/metabolism | 2 | 1.0 |
Cations, Divalent | 2 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/*genetics | 2 | 50.0 |
Cytopathogenic Effect, Viral | 3 | 2.0 |
Staphylococcus aureus | 2 | 3.0 |
Lymphocytes/drug effects | 3 | 4.0 |
Autoantibodies/immunology | 2 | 1.0 |
Antigens, Surface/genetics | 3 | 6.0 |
*Chromosomes, Human, Pair 19 | 2 | 0.0 |
Immunoglobulins, Fab/*immunology | 3 | 11.0 |
T-Lymphocytes, Cytotoxic/*physiology | 3 | 25.0 |
Antigens, Differentiation/*immunology | 20 | 14.0 |
Adenosine Diphosphate Ribose/metabolism | 3 | 5.0 |
GTP-Binding Proteins/*physiology | 3 | 2.0 |
Heat | 2 | 0.0 |
Cadmium Chloride | 2 | 33.0 |
Dose-Response Relationship, Radiation | 3 | 0.0 |
Fetus/immunology | 2 | 5.0 |
Histocompatibility Antigens/*immunology | 4 | 16.0 |
Antigens, Surface/*analysis/immunology | 4 | 22.0 |
Luminescent Measurements | 2 | 2.0 |
Antigens, Differentiation/analysis/immunology | 2 | 22.0 |
Phosphatidylserines/*biosynthesis | 3 | 50.0 |
T-Lymphocytes/drug effects/*metabolism | 2 | 4.0 |
RNA/analysis | 2 | 0.0 |
Receptors, Antigen, T-Cell/*metabolism/physiology | 3 | 50.0 |
Anti-Bacterial Agents/*pharmacology | 2 | 1.0 |
Cyclosporins/*pharmacology | 3 | 8.0 |
Tacrolimus | 2 | 50.0 |
Antigens, Differentiation, B-Lymphocyte/physiology | 2 | 10.0 |
Crohn Disease/immunology | 2 | 13.0 |
Farmer's Lung/immunology | 2 | 100.0 |
Lung/*immunology | 2 | 4.0 |
Antigens, Differentiation/immunology | 6 | 5.0 |
Inositol/metabolism | 3 | 12.0 |
Phosphoprotein Phosphatase/*metabolism | 2 | 2.0 |
Protein-Tyrosine-Phosphatase | 3 | 17.0 |
Receptors, Interleukin-2/drug effects/metabolism | 3 | 30.0 |
Antigen-Antibody Complex | 4 | 2.0 |
Antigens, Differentiation/*genetics | 2 | 1.0 |
Fatigue Syndrome, Chronic/*immunology | 2 | 25.0 |
Receptors, Immunologic/*biosynthesis | 3 | 13.0 |
*Fluorescent Antibody Technique | 2 | 8.0 |
Urine/*cytology | 2 | 22.0 |
*Cell Adhesion/drug effects | 2 | 9.0 |
Interleukin-2/*therapeutic use | 3 | 2.0 |
T-Lymphocytes/microbiology/*physiology | 2 | 40.0 |
Receptors, Fc/*immunology | 5 | 15.0 |
Killer Cells, Natural/drug effects | 2 | 5.0 |
Lymphocytes/immunology/*physiology | 2 | 11.0 |
Receptors, Leukocyte-Adhesion/*physiology | 5 | 41.0 |
RNA-Directed DNA Polymerase/metabolism | 2 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/immunology/physiology | 4 | 80.0 |
Antibodies, Monoclonal/diagnostic use/immunology | 3 | 11.0 |
Phospholipase C/metabolism | 5 | 1.0 |
Fluorides/pharmacology | 3 | 10.0 |
Phagocytosis | 4 | 1.0 |
HIV Seropositivity/*immunology | 2 | 2.0 |
T-Lymphocytes/drug effects | 2 | 3.0 |
Epitopes/analysis | 6 | 2.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Mediastinum | 2 | 33.0 |
Gene Rearrangement, T-Lymphocyte/genetics | 3 | 16.0 |
CD4-Positive T-Lymphocytes/immunology/*physiology | 2 | 15.0 |
Plasma Cells/immunology | 2 | 7.0 |
Receptors, Antigen, T-Cell/immunology/physiology | 2 | 50.0 |
Receptors, Immunologic/immunology/physiology | 2 | 50.0 |
Receptors, Lymphocyte Homing | 6 | 16.0 |
Leukemia, Lymphocytic, Acute/immunology/*pathology | 3 | 33.0 |
Avidin | 2 | 13.0 |
HIV-1/genetics/*immunology | 2 | 2.0 |
Drug Evaluation | 2 | 0.0 |
Brain Neoplasms/*immunology | 2 | 15.0 |
Glioma/*immunology | 2 | 13.0 |
Erythrocyte Membrane/immunology | 2 | 5.0 |
Colony-Stimulating Factors/*pharmacology | 2 | 4.0 |
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 3.0 |
Growth Substances/*pharmacology | 4 | 1.0 |
Interleukin-1/*pharmacology | 3 | 0.0 |
Killer Cells, Natural/metabolism | 2 | 3.0 |
Blood Physiology | 2 | 2.0 |
Adenylate Cyclase/metabolism | 2 | 1.0 |
Virulence Factors, Bordetella/pharmacology | 2 | 1.0 |
Ferric Compounds/pharmacology | 2 | 18.0 |
Cell Membrane Permeability/drug effects | 2 | 3.0 |
DNA Replication | 4 | 1.0 |
Diglycerides/pharmacology | 3 | 8.0 |
Interferon Type II/genetics | 2 | 2.0 |
Antigens, Surface/*genetics | 5 | 7.0 |
Nucleic Acid Hybridization | 9 | 0.0 |
Lymphocyte Function-Associated Antigen-1 | 37 | 48.0 |
Antibodies, Monoclonal/immunology/physiology | 2 | 40.0 |
Peptide Fragments | 2 | 2.0 |
Leukemia/genetics/immunology/*pathology | 2 | 40.0 |
Lymphokines/pharmacology | 3 | 1.0 |
Phosphatidylinositols/*metabolism | 2 | 2.0 |
Thymus Gland/cytology/*physiology | 2 | 22.0 |
Paraffin | 2 | 4.0 |
Phospholipids/metabolism | 2 | 1.0 |
*Antigens, Differentiation, T-Lymphocyte | 8 | 25.0 |
Antigens, CD27 | 13 | 30.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology/physiology | 2 | 66.0 |
DNA/*analysis | 2 | 0.0 |
Pemphigoid, Bullous/*immunology | 2 | 11.0 |
*Receptors, Antigen, T-Cell | 4 | 33.0 |
Immunoglobulins, Fab/pharmacology | 2 | 9.0 |
Antigens | 3 | 3.0 |
Egypt | 2 | 4.0 |
Leukemia, T-Cell, Acute/immunology/*pathology | 2 | 50.0 |
Antigens, Surface | 2 | 3.0 |
Interferon Type I, Recombinant/*therapeutic use | 2 | 16.0 |
Cholera Toxin/*pharmacology | 2 | 12.0 |
Down-Regulation/drug effects | 2 | 0.0 |
Antigen-Antibody Complex/immunology | 2 | 3.0 |
Peptide Fragments/analysis | 2 | 0.0 |
Inflammation/*immunology | 2 | 3.0 |
Antibodies, Monoclonal/physiology | 17 | 23.0 |
T-Lymphocytes/*immunology/metabolism/physiology | 2 | 28.0 |
Antigens, Surface/immunology/physiology | 2 | 66.0 |
CD4-Positive T-Lymphocytes/classification/*immunology | 2 | 33.0 |
Interleukin-4 | 3 | 3.0 |
Dinoprostone/pharmacology | 2 | 2.0 |
Isoquinolines/pharmacology | 2 | 1.0 |
Phorbol 12,13-Dibutyrate/*pharmacology | 2 | 11.0 |
Piperazines/pharmacology | 2 | 1.0 |
Receptors, Transferrin/immunology | 2 | 25.0 |
Complement/*pharmacology | 2 | 15.0 |
T-Lymphocytes/*classification | 2 | 5.0 |
Cyclophosphamide/*therapeutic use | 2 | 7.0 |
Lupus Erythematosus, Systemic/*drug therapy/immunology | 2 | 33.0 |
Killer Cells/immunology | 2 | 7.0 |
T-Lymphocytes/*classification/immunology | 3 | 10.0 |
Antigens, Surface/*immunology/isolation & purification | 4 | 50.0 |
T-Lymphocytes/*analysis | 2 | 14.0 |
Antigens, CD4/*biosynthesis | 3 | 6.0 |
Lymphocytes/*classification | 3 | 17.0 |
Leukocyte Count/methods | 2 | 25.0 |
Thymus Gland/cytology/embryology | 2 | 33.0 |
T-Lymphocytes/classification/*immunology | 11 | 16.0 |
Killer Cells/*immunology | 3 | 8.0 |
Immunoglobulins, Fab/physiology | 2 | 28.0 |
Lymphocytosis/immunology | 2 | 50.0 |
Dextran Sulfate | 2 | 9.0 |
Leukocytes, Mononuclear/analysis | 2 | 50.0 |
Adjuvants, Immunologic/*physiology | 2 | 6.0 |
Antibodies, Monoclonal/*physiology | 9 | 23.0 |
T-Lymphocytes/analysis/*immunology | 2 | 40.0 |
Antigens, Heterophile/*immunology | 2 | 16.0 |
Receptors, Antigen, T-Cell/*analysis/immunology | 2 | 40.0 |
Cell Fractionation | 3 | 1.0 |
Leukemia, Lymphocytic/genetics/*immunology | 2 | 66.0 |
T-Lymphocytes/classification/immunology/physiology | 2 | 100.0 |
T-Lymphocytes, Cytotoxic/classification/*immunology | 2 | 13.0 |
Gene Expression Regulation/drug effects | 4 | 0.0 |
*Antigens, Surface | 2 | 2.0 |
Immunoglobulins, Surface/analysis | 3 | 6.0 |
Tetradecanoylphorbol Acetate | 3 | 4.0 |
Stem Cells/classification/metabolism/physiology | 2 | 100.0 |
Culture Media/pharmacology | 2 | 2.0 |
Ionomycin | 2 | 8.0 |
Fabaceae | 2 | 28.0 |
Plants, Medicinal | 2 | 4.0 |
Immunosuppressive Agents/physiology | 2 | 28.0 |
T-Lymphocytes/enzymology/immunology/*metabolism | 2 | 40.0 |
Killer Cells, Natural/classification/*immunology | 2 | 33.0 |
DNA/biosynthesis | 3 | 0.0 |
Collodion | 2 | 5.0 |
Pregnancy/*immunology | 2 | 3.0 |
Leprosy/*immunology | 2 | 8.0 |
Cyclic AMP/*physiology | 2 | 2.0 |
Precipitation | 2 | 1.0 |
Receptors, Interleukin-2 | 16 | 14.0 |
Receptors, Antigen, T-Cell/genetics/*immunology | 2 | 12.0 |
Trypsin | 2 | 1.0 |
Antigens, Surface/analysis/*immunology | 2 | 16.0 |
T-Lymphocytes, Cytotoxic/*immunology/metabolism | 2 | 5.0 |
T-Lymphocytes/*classification/immunology/metabolism | 3 | 75.0 |
Tumor Cells, Cultured/analysis | 2 | 13.0 |
Carrier Proteins/*physiology | 3 | 1.0 |
*Genes, Immunoglobulin | 2 | 1.0 |
Erythrocytes/*metabolism | 2 | 0.0 |
Sheep/blood | 2 | 14.0 |
Leukemia/therapy | 2 | 5.0 |
Leukemia, Lymphocytic/*immunology | 2 | 6.0 |
Erythrocyte Membrane/*immunology | 3 | 6.0 |
Sheep/*immunology | 2 | 15.0 |
DNA/*metabolism | 2 | 0.0 |
Erythrocytes/analysis | 2 | 8.0 |
Lymphoma/*genetics/pathology | 2 | 15.0 |
Growth | 2 | 4.0 |
Antigens, Surface/analysis/*genetics | 2 | 20.0 |
Graft Rejection | 2 | 1.0 |
Models, Genetic | 2 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Phorbols/*pharmacology | 2 | 5.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
*Cytoskeletal Proteins | 2 | 1.0 |
Clone Cells/pathology | 2 | 3.0 |
Isoenzymes/metabolism | 2 | 0.0 |
